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Background: Alcohol and Free fatty acids such as palmitate are known to 
promote liver injury. However less mechanistic information is available regarding 
omega fatty acids ratios with/out alcohol.  In healthy populations omega 6/3 ratios 
are between 1:1 to 4:1, whereas high ratios (>15:1) are thought to correlate with 
the pathogenesis of fatty liver disease. This study aimed to investigate liver 
lipotoxicity and mitochondrial dysfunction due to imbalanced omega 6/3 ratios 
alone or in the presence of alcohol. 
Method: Human hepatoma cell line, VL-17A cells were treated with individual 
fatty acids (Palmitic (PA), Stearic (SA), Linoleic (LA), alpha-Linolenic (ALA), 
Arachidonic (AA) and Docosahexaenoic (DHA) acids) with various 
concentrations ranging between 0.5 µM to 300 µM and omega 6/3 ratios (1:1, 
4:1, 15:1 and 25:1) with/out alcohol (100 mM) for 24, 48 and 72 h after which lipid 
accumulation and cell toxicity was assessed. Subsequent studies at 24 hr 
examined oxidative stress, mitochondrial function and lipogenic proteins.  
Results: PA treatment showed a detrimental effect on cell viability and lipid 
accumulation than SA after 48 h and 72 h (P<0.05); omega 3 (ALA and DHA) did 
not show any significant effect; LA exhibited a significant reduction in cell viability 
at 24 h only without causing any change in lipid accumulation; AA treatment 
significantly reduced cell viability at 48 h and 72 h (P<0.05) but only showed a 
significant lipid accumulation after 48 h. AA/DHA (omega 6/3) ratios (15:1 & 25:1) 
caused a significant reduction in cell viability after 24 h, 48 h and 72 h (P<0.001) 
and only (15:1) ratio inversely corresponded to an elevation in lipid level after 24 
h and 48 h (P<0.01). At 24 hr treatment, high AA/DHA ratio of 25:1 led to 
increased expression of stearoyl-CoA desaturase (SCD1) and decreased 
peroxisome proliferator activated receptor alpha (PPARα) expression at 15:1 and 
25:1 (P<0.05), while all ratios showed a significant decrease in the cannabinoid 
receptor (CB2) expression compared to control but actually increased when 
compared to the 1:1 ratio. Although the expression of CB1 was slightly increased 
(P>0.05), sterol regulatory element-binding protein 1 (SREBP1) did not show any 
change.  AA/DHA ratios also showed a significant decrease in ATP production 
(P<0.01), basal respiration, maximal respiration and spare mitochondrial capacity 
and this effect was greater with high ratios (P<0.001). Reactive oxygen species 
(ROS) production increased significantly, particularly with high AA/DHA ratios 
(15:1 and 25:1) (P<0.001) alone and in the presence of alcohol (P<0.01).  
Conclusion: The data suggests that lipid accumulation and toxicity occur with 
saturated and unsaturated fatty acids and high omega 6/3 ratios. The latter 
possibly due to the pro-inflammatory products of AA. This study confirms that 
high AA/DHA ratios with/out alcohol increase ROS production and high AA/DHA 
alone induce mitochondrial dysfunction and increase lipogenesis pathways by 
activating lipogenic factors causing steatosis and consequently promoting the 
development of fatty liver disease. Further work aims to elucidate the effect of 
fatty acid/alcohol on lipid synthetic and endocannabinoid pathways, which will 
further our understanding of fatty liver disease development. 
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1. 1 Global burden of non-alcoholic fatty liver disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) is a chronic disease with a high 
prevalence rate worldwide. NAFLD is considered the second major cause of 
mortality in the world with a serious economic load for numerous countries due 
to its passive pathological consequences (Yao et al., 2016). The prevalence of 
NAFLD has doubled since 1980. It occurs in approximately 20-40% of Western 
and Asian populations and affects almost one-third of the world’s population of 
different ages and races (Gentile and Pagliassotti, 2008; Wree et al., 2010; 
Williams et al., 2011; Takahashi et al., 2015; Yao et al., 2016) (Table 1.1). In 
addition, up to a third of the United Kingdom’s population being affected by 
NAFLD whereas in the United States, about 80 to 100 million individuals are 
afflicted by NAFLD, in whom around 30% may suffer from non-alcoholic 
steatohepatitis (NASH), the progressive stage of NAFLD (Dyson et al., 2014; 
Patel et al., 2016).  NASH also affects around 12% of middle-aged people and is 
now the third-leading cause of liver transplantation in the United States and in the 
United Kingdom (McCullough, 2006; Charlton et al., 2011; Takahashi et al., 
2015).   
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Table 1.1: Prevalence of NAFLD in general population across regions (WGO, 2012).  
 
 
 
The high correlation between NAFLD and type II diabetes mellitus has 
significantly increased the prevalence of NAFLD worldwide to approximately 
21%-78% (Olusanya et al., 2016). Moreover, the expansion of sedentary 
lifestyles as well as the increased consumption of unhealthy and imbalanced diets 
has led to an increase in the number of obese individuals (Figure 1.1) and, 
consequently, the prevalence of NAFLD in places such as South Africa, where 
about 45% of obese individuals were found to be affected by NAFLD (Olusanya 
et al., 2016; Severson et al., 2016). In addition, one-third of America’s population 
suffer from obesity, with 30% being affected by NAFLD (Vernon et al., 2011). 
 
Region  Population category  NAFLD prevalence (%) 
USA Children 
General population 
13-14  
27-34 
Europe Children 
General population 
2.6-10 
20-30 
Western countries General population 20-40 
Middle East General population 20-30 
Far East General population 15 
Pakistan General population  18 
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Figure 1.1: Global prevalence of obesity in both sexes,  ages 18 +. Source: 
For more on the WHO Global Health Observatory Map Gallery on non 
communicable diseases see http://gamapserver.who.int/mapLibrary 
 
  
5 
 
1.2 Pathogenesis of NAFLD  
NAFLD is caused by high dietary fat or carbohydrate consumption and is not 
related to excessive alcohol use. As previously mentioned, NAFLD is also highly 
related to the incidence of some metabolic syndromes, such as obesity, type II 
diabetes and insulin resistance (Wree et al., 2010; Mota et al., 2016). The latter 
is believed to be one of the vital factors involved in the development of NAFLD, 
as it increases the breakdown of adipose tissue causing an increase in the level 
of free fatty acids in circulation, which, in turn, gives rise to liver steatosis 
(Papandreou and Andreou, 2015). Simple hepatic steatosis is the first 
manifestation of NAFLD. This disease is known to have a broad spectrum and 
develops into NASH; this condition is characterised by hepatic ballooning, 
inflammation and fibrosis, which may then progress rapidly into cirrhosis and in 
some cases, ultimately lead to hepatocellular carcinoma (HCC) (Gusdon et al., 
2014).  
 
1.2.1 Multi-hit hypothesis 
The multi-hit theory is a global hypothesis for the pathogenesis of NAFLD, which 
comprises three theories. Gentile and Pagliassotti (2008) described the ‘first hit’ 
as the stage where triglycerides (TG) accumulate in the hepatocyte (steatosis) 
and make the liver more susceptible to injury by many mediators. These include 
elevated levels of the leptin hormone and some cytokines, such as tumour 
necrosis factor (TNF-α) and interleukin-6 (IL-6), in the serum as well as 
mitochondrial dysfunction, oxidative stress and endoplasmic reticulum stress 
(ER), which, in turn, lead to the development of NASH. This stage is known as 
the ‘second hit’ (Dowman et al., 2010). The second-hit theory was proposed in 
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1998 by Day et al. and it is believed that this theory plays a crucial role in 
understanding the pathogenesis of NAFLD, which may in some cases be 
accompanied by the occurrence of fibrosis and then develop to cirrhosis ‘third hit’ 
(Figure 1.2) (Gentile and Pagliassotti, 2008).  
 
Indeed, despite the existing literature on this topic, the pathogenesis of fatty liver 
disease is still largely unclear. In addition, most patients with NAFLD are 
asymptomatic until the developed stages of the disease, and currently, the only 
reliable diagnostic method in use is liver biopsy, which provides precise data on 
the grading of fibrosis (Wang and Liu, 2003; Adams et al., 2005; Gyamfi and Wan, 
2010; Papandreou and Andreou, 2015).  
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1.3 Role of free fatty acids and some molecular mediators in the 
development of NAFLD 
The accumulation of free fatty acids in the hepatocytes due to hyperinsulinemia 
or hyperglycemia is regulated by the transcriptional factor sterol regulatory 
element-binding protein 1c (SREBP1c), peroxisome proliferator-activated 
receptor (PPAR-α) and high dietary fat (Mantena et al., 2009; Tsochatzis et al., 
2009).  Also, how stearoyl-CoA desaturase (SCD1) and cannabinoid receptors 
intervene in the development of this disease is to be discussed in this chapter.   
 
1.3.1 Role of SREBP1c 
SREBP family is involved in controlling some genes that are coded for some 
proteins in lipid metabolism, such as 3-hydroxy-methylglutaryl-CoA (HMG-Co A) 
reductase, Acetyl-CoA carboxylase, fatty acid synthase (FAS) and low density 
lipoprotein (LDL) receptor. These proteins are employed in the regulation of lipid 
and carbohydrate metabolism by controlling the lipogenesis and 
gluconeogenesis pathways (Chakravarty et al., 2004; Mullen et al., 2004; Quan 
et al., 2013; Peng et al., 2016). Mammals have two SREBP genes, SREBP1 and 
SREBP2. SREBP1a and c isoforms are responsible for regulating the metabolism 
of fatty acids and are encoded by a single gene known as SREBF-1. On the other 
hand, SREBP2 is the master regulator of cholesterol metabolism but has been 
found as weak regulator of fatty acids biosynthesis and is encoded by a different 
gene, SREBF-2. SREBP1a, is a potent transcriptional activator of genes encoded 
for enzymes involved in the biosynthesis of fatty acids and cholesterol, while 
SREBP1c activates transcription of enzymes contributing in the synthesis of 
unsaturated fatty acids (DeBose-Boyd et al., 2001). SREBP1c is a lipogenic 
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transcriptional factor that is predominantly found in the liver, skeletal muscles and 
adipose tissue. It is also believed that SREBP1c is involved in controlling the 
enzymatic synthesis of TG and fatty acids in the liver. (Chakravarty et al., 2004; 
Mullen et al., 2004; Quan et al., 2013; Peng et al., 2016). Insulin resistance and 
diabetes are highly associated with NAFLD in which the latter is a consequence 
of SREBP1c overexpression (Figure 1.3) (Vitto et al., 2012). 
 
1.3.2 Role of SCD1 
SCD1 is a delta 9 desaturase enzyme involved in the biosynthesis of unsaturated 
fatty acids. It is highly expressed in the liver and this rate-limiting enzyme converts 
saturated fatty acids into monounsaturated fatty acids by adding a cis double 
bond to the delta 9th carbon of fatty acyl CoA (Gutiérrez-Juárez et al., 2006; 
Matsui et al., 2012; Caputo et al., 2014). Thus, stearoyl-CoA and palmitoyl-CoA, 
which are saturated fatty acids, are transformed by SCD1 into oleoyl-CoA and 
palmitoleoyl-CoA, respectively. SCD1 plays a vital role in hepatic lipid oxidation 
and lipogenesis. The produced monounsaturated fatty acids act as structural 
components of the cellular membrane phospholipid and are considered to be 
preferred substrates in the synthesis of complex lipids, such as TG and 
cholesterol ester. These complex lipids intervene in apoptosis, membrane fluidity, 
transduction signalling and energy metabolism (Matsui et al., 2012; Zhang et al., 
2013; Caputo et al., 2014).  Various factors, such as insulin, polyunsaturated fatty 
acids, fructose and glucose, can regulate SCD1 expression (Ntambi et al., 2004). 
Moreover, liver X receptor (LXR) activation, positively regulates the expression 
of SCD1 and promotes lipogenesis. This regulation can occur either (a) directly 
by the binding of LXR to the SCD1 gene promoter via an LXR response element 
or (b) indirectly by the activation of SREBP1-c transcription via LXR (Kim et al., 
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2002; Liang et al., 2002; Chu et al., 2006). Therefore, as mentioned previously, 
the activation of SREBP1c will activate some lipogenic enzymes involved in the 
synthesis of TG and consequently induce hepatic steatosis.   
.    
1.3.3 Role of PPAR-α 
PPAR is another nuclear ligand-activated transcriptional factor that acts as a 
hormonal receptor, which belongs to the steroid family receptors. It is involved in 
fatty acids metabolism and plays a vital role in fatty acids oxidation (Gyamfi and 
Patel, 2009; Grygiel-Górniak, 2014; Blednov et al., 2016). PPAR has two binding 
domains; the first domain binds to the deoxyribonucleic acid (DNA) sites of the 
target gene, which are called peroxisome proliferator hormone response 
elements (PPREs), via the DNA-binding domain located in the N-terminus of the 
PPAR, whereas the C-terminal has the ligand-binding second domain. Thus, after 
interacting with some ligands, it is translocated to the nucleus and induces gene 
transcription by changing its structure (Grygiel-Górniak, 2014). PPARs have 
three different isoforms: PPARγ, PPARβ/δ and PPAR-α (Berger and Moller, 
2002). The latter is highly expressed in the brown adipose tissue, skeletal 
muscles, liver and heart. Therefore, when it is activated, it plays an important role 
in fatty acids oxidation and in lowering the level of lipids and consequently fat 
storage, and it prevents steatosis (Rao and Reddy, 2004; Neschen et al., 2007). 
However, inactivating PPAR-α reduces the oxidation of free fatty acids and 
energy utilisation, causing liver steatosis, which may develop into NASH (Figure 
1.3) (Schwimmer et al., 2005).  PPAR isoforms differ from one another in their 
sites of distribution and physiological effects, so they either activate or inhibit the 
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various genes involved in lipid and glucose haemostasis (Willson et al., 2000; 
Sertznig et al., 2007).  
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Figure 1.3: Mechanisms into fatty liver disease. 
The accumulation of FFA through the ingestion of high fat diet leads to an increase 
in the intracellular lipogenesis and the synthesis of endocannabinoids. The latter, 
stimulates the activation of CB1 and CB2 receptors. Both mechanisms result in 
activating and deactivating some lipogenic genes SREBP1-c and PPARα, 
respectively. This effect consequently, increases FA synthesis and reduces FA 
oxidation causing cell death due to lipotoxicity caused by an increase of fat. 
Another crucial mechanism that can also lead to cell death is the disturbance of 
the mitochondrial ETC by destabilising the inner mitochondrial membrane. This in 
turn, causes loss in the membrane potential and mitochondrial swelling as a result 
of electron leakage and oxidative phosphorylation uncoupling of the respiratory 
chain, which then reduces the production of ATP. ETC disturbance also increases 
the production of ROS and consequently increases oxidative stress which has the 
ability to damage the complexes of the ETC and causes cell death. FFA, free fatty 
acid; FA, fatty acid; SREBP1-c, sterol regulatory element binding protein 1-c; 
PPAR-α, Peroxisome proliferator-activated receptors; ETC, electron transport 
chain; ROS, reactive oxygen species.  
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1.3.4 Role of Free Fatty acids  
Free fatty acids play a crucial role in developing NAFLD by causing liver 
mitochondrial dysfunction through disturbing the electron transport chain (ETC) 
in the liver mitochondria and consequently reducing the production of the 
adenosine triphosphate (ATP) (Figure. 1.3) (Mantena et al., 2009; Tsochatzis et 
al., 2009).  
 
Electron transport chain (ETC) 
To understand how the ETC is involved in the development of NAFLD, it is 
necessary to describe this briefly in this chapter. In fact, the main function of ETC 
is energy production in the form of ATP, which is generated mainly via fat and 
carbohydrate oxidation under aerobic condition in the inner mitochondrial 
membrane and the cytoplasm, respectively. This process is recognised as 
oxidation phosphorylation and comprises (a) a respiratory chain that has four 
complexes and (b) the stage of ATP synthesis (Schon et al., 2010). 
 
Five multiprotein complexes (I-V) exist in the ETC, along with two electron 
carriers (coenzyme Q and cytochrome C). Normally, electrons are released from 
reduced Flavin adenine dinucleotide (FADH2) and nicotinamide adenine 
dinucleotide (NADH), which are generated from the oxidation of Acetyl-coA in the 
Krebs cycle, and subsequently, they pass through the respiratory chain and 
reduce the oxygen atom in complex IV to form water. The movement of electrons 
across the ETC will produce energy because of the redox reactions, where the 
electron transfers from an electron donor to an electron acceptor. This energy will 
then be used in generating an electrochemical proton gradient across the inner 
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membrane of the mitochondria by pumping protons (H+) from the matrix of the 
mitochondria to the intermembrane space, across the respiratory chain (Acın-
Perez et al., 2008; Schon et al., 2010; Nassir and Ibdah, 2014). As a result, ETC 
will be coupled with oxidative phosphorylation via an electrochemical gradient, 
and therefore, the energy that this gradient generates will be used to produce 
ATP from inorganic phosphate (P) and adenosine diphosphate (ADP) in complex 
V (ATP synthase) via oxidative phosphorylation (Figure. 1.4) (Acın-Perez et al., 
2008).  
 
Reactive oxygen species 
Complexes (I & III) are considered the main sites of electron leakage in the inner 
mitochondrial membrane. Normally, reactive oxygen species (ROS) are 
produced in the mitochondria by complex I and III via the reduction of oxygen to 
the superoxide anion (Nassir and Ibdah, 2014).  However, the excessive flow of 
electrons to the respiratory chain will cause the accumulation of electrons and 
results in electron leakage, leading to oxygen-forming ROS (Murphy, 2009). 
Indeed, electron leakage prevents complex IV from reducing a molecular oxygen 
atom to water, allowing the formation of a free radical, such as the superoxide 
anion (Mantena et al., 2008; Schönfeld and Wojtczak, 2008). Under physiological 
conditions, about 1%-2% of the oxygen atoms in the mitochondria are consumed 
to produce ROS, where some of them act as strong oxidising factors and play 
major roles in signalling pathways (Boveris and Chance., 1973; Leamy et al., 
2013). Mitochondria plays a prime role in the homeostasis of ROS as the 
mitochondrial production of ROS accounts for 90% of the cellular production 
(Balaban et al., 2005; Nassir and Ibdah, 2014).  
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The increased production of ROS, particularly the superoxide anion in the 
mitochondria, results in the elevation of oxidative stress, such as in NASH, where 
the oxidation of free fatty acids increases (Begriche et al., 2006; Nassir and Ibdah, 
2014). Accordingly, a high level of oxidative stress in the mitochondria can 
damage complexes (I-IV) of the ETC leading to cell death. ROS molecules, such 
as hydrogen peroxide, hydroxyl radicals and superoxide radicals, have the 
oxidative ability to damage DNA as well as the membrane of the cell. The latter 
is induced through the production of the lipid diffusible molecules known as 
reactive aldehydes, such as malondialdehyde and 4-hydroxynonenal. These two 
molecules also activate hepatic stellate cells, leading to collagen synthesis and 
the development of liver fibrosis (Bailey and Cunningham, 2002; Fromenty, et al., 
2004; Mantena et al., 2008; Schönfeld and Wojtczak, 2008; Leamy et al., 2013; 
Papandreou and Andreou, 2015). 
 
A high ROS level usually occurs in response to some factors, such as depletion 
in the antioxidant defence, cellular stress and mitochondrial dysfunction (Leamy 
et al., 2013). The latter is also caused by electron leakage that causes 
mitochondrial membrane potential destabilisation, which, in turn, impairs the flow 
of electrons in the ETC and consequently increases the permeability of the inner 
mitochondrial membrane. This leads to mitochondrial swelling, the loss of the 
mitochondrial membrane potential via oxidative phosphorylation uncoupling and, 
subsequently, ATP synthesis reduction (Mantena et al., 2009; Tsochatzis et al., 
2009).  
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 1.3.5 Role of cannabinoids receptors (CB1, CB2) 
Cannabinoids are chemical compounds that exist in three different forms: 
phytocannabinoids, which can be found in some plants and cannabis; 
endocannabinoids, which are synthesised naturally in the human body; and 
ultimately, synthetic cannabinoids, which can be chemically synthesised. Two 
types of cannabinoid receptors exist: CB1 and CB2. CB1 receptors are highly 
expressed in the brain and the central nervous system also has been found 
located in some glands like pituitary gland and organs as the liver and pancreas, 
whereas CB2 receptors can be found in the cells of the immune system and 
haematopoietic cells (Rice et al., 1997; Pagotto et al., 2001; Purohit et al., 2009; 
Purohit et al., 2010; Alswat, 2013). CB1 and CB2 receptors have also been 
identified in the human liver, and it is believed that the activation of these two 
receptors is implicated in the development of fatty liver disease (Julien et al., 
2005; Teixeira-Clerc et al., 2006; Mendez-Sanchez et al., 2007; Purohit et al., 
2010; Alswat, 2013). 
 
Alswat (2013) stated that 66 cannabinoids can be isolated from cannabis. In 
cannabis sativa L, tetrahydrocannabinol (THC), is the principle active component, 
and besides its therapeutic effect, it is also implicated in the production of an 
undesirable effect following the activation of CB1 receptors in the central nervous 
system. Cannabidiol (CBD) is another active constituent in cannabis extract (up 
to 40%), which can exhibit a pharmacological effect without any side effects 
(Alswat, 2013). 
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 As Purohit et al. (2010) demonstrated, obesity and the high consumption of fat 
and alcohol play fundamental roles in increasing the synthesis of 2-
arachidonoylglycerol (2-AG) and archidonoylethanolamide (anandamide), both of 
which are considered the main discovered endogenous endocannabinoids. The 
elevated level of these endocannabinoids will activate CB1 receptors and 
stimulate the expression of SREBP1c and its target enzymes, FAS and acetyl-
CoA carboxylase-1, thus decreasing the regulation of the rate-limiting enzyme in 
fatty acid β-oxidation and carnitine palmitoyltransferase-1. Accordingly, the de 
novo synthesis of fatty acids will increase, whereas the oxidation of fatty acids 
will decrease, leading to the development of fatty liver. High fat consumption also 
contributes to the development of fatty liver and NAFLD via the activation or 
upregulation of CB2 receptors, however, their role in NAFLD is still not clear and 
needs further investigation. Interestingly, it has also been reported that CB1 and 
CB2 receptors act as profibrogenic and antifibrogenic activators, respectively 
(Figure. 1.3) (Julien et al., 2005; Teixeira-Clerc et al., 2006; Purohit et al., 2010).  
Inhibition of CB1 receptors can be a promising treatment approach and may have 
a potential therapeutic effect in managing NAFLD (Alswat, 2013). Indeed, 
understanding this mechanism can significantly help in finding a reliable 
treatment for this disease by inhibiting CB1 receptors to prevent the prognosis 
and development of fatty liver disease. 
 
1.4 Fatty acid classification and omega 6 and 3 metabolism 
Most natural fatty acids consist of an even carbon chain with carboxyl (COOH) 
and methyl (CH3) terminals (Kelly and Scheibling, 2012). Two classes of fatty 
acids exist: saturated and unsaturated. Stearic (18:0) and palmitic (16:0) acids 
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are examples of saturated fatty acids, which have no double bonds in their carbon 
chains and are considered the major dietary saturated fatty acids found in the 
blood circulation. They account for approximately 30-33% of plasma fatty acids. 
Saturated fatty acids are non-essential fatty acids, which can be synthesised in 
the body. They are found in meat, butter, whole milk, dairy products, palm oil and 
coconut oil (Schaefer et al., 2000). 
 
On the other hand, unsaturated fatty acids are essential fatty acids, and most of 
these acids must be obtained from one’s diet, as they cannot be produced in the 
body, especially if the double bond needs to be placed in carbon 6 or 9. They are 
subdivided into two groups according to the number of double bonds in their 
carbon chains. Monounsaturated fatty acids constitute about 20% of plasma fatty 
acids, and each has only one double bond, such as omega 9 oleic acid (18:1n9), 
with the double bond being located at carbon 9 from the methyl terminal 
(Schaefer et al., 2000). Monounsaturated fatty acids can be found in avocados 
as well as in canola and olive oil. Polyunsaturated fatty acids constitute the 
second class of unsaturated fatty acids, such as omega 6 and omega 3, which 
each having more than one double bond that is separated by a methylene group 
(CH2). The double bond in the carbon chain usually allows the chain to kink in a 
37-degree angle and consequently improves the fluidity of the cellular membrane. 
In addition, most natural unsaturated fatty acids have a cis configuration, where 
the two hydrogen atoms lie on the same side of the carbon chain, which is counter 
to the trans configuration, where the two hydrogen atoms occur on opposite sides 
of the hydrocarbon chain. This happens as a result of hydrogenation (Calder., 
2008; Wall et al., 2010; Schaefer et al., 2000). 
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The importance of omega 6 and 3 is centered on regulating various biological 
functions, such as regulating blood clotting and blood pressure (Wall et al., 2010). 
They are also considered a major component of the cell membrane, where they 
maintain the fluidity of the membrane, (Das, 2005). Omega 6 and 3 also play 
significant roles in the functioning and development of the brain and nervous 
system as well as in regulating inflammatory and immune responses (Williams, 
2000).  
 
The difference between omega 6 and 3 is the position of the first double bond 
from the methyl end of the fatty acid chain. Linoleic acid (LA, 18:2) and α-linolenic 
acid (ALA, 18:3) are the precursors of omega 6 and omega 3, respectively, and 
they cannot be produced in the body due to the lack of desaturase enzymes, 
which are required in their production. Cereals, egg, butter, whole grain breads, 
nuts and vegetable oil, such as corn and sunflower oil, are the main sources of 
omega 6, whereas omega 3 is found in green leafy  vegetables, canola, walnut, 
flaxseeds and fish (El-Badry et al., 2007; Simopoulos, 2008; Rustichelli et al., 
2009; Kelly and Scheibling, 2012; Patterson et al., 2012; Elhardallou et al., 2014). 
It has been found that omega 3 and omega 6 fatty acids are correlated with the 
pathogenesis of NAFLD due to the dietary imbalance between them where the 
omega 6 concentration is higher than omega 3 (Santoro et al., 2012). However, 
the exact pathogenic mechanism for this is unclear. Therefore, it is important to 
understand and to identify how they affect intracellular lipid metabolism and 
NAFLD pathogenesis.  
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Omega 6 and 3 metabolism 
Briefly, LA and ALA are metabolised mainly in the liver but also in some other 
tissues by adding one double bond by the delta 6-desaturase enzyme to the 
carboxyl end of the chain as the first and rate-limiting step in this pathway. Both 
fatty acids continue to elongate through the enzyme elongation of very long chain 
fatty acids 5 (ELOVL 5), and they desaturate to a longer fatty acid chain. Thus, 
LA generates arachidonic acid (AA, 20:4), whereas ALA is metabolised to 
eicosapentaenoic acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:6) 
(Figure 1.5) (Simopoulos, 2008; Candela, et al., 2011)  
 
Omega 6 and omega 3 compete for the desaturation enzymes, but both delta-5 
and delta-6 desaturase enzymes prefer the desaturation of omega 3 fatty acids 
rather than those of omega 6. Therefore, the high dietary intake of LA interferes 
with the elongation and desaturation of ALA (El-Badry et al., 2007; Simopoulos, 
2008; Candela, et al., 2011). It is known that delta-6 desaturase decreases with 
age and in some cases in hypertensive and diabetic individuals as well as in 
premature infants, where the ability to produce EPA and DHA is limited 
(Simopoulos, 2008). It is also known that hormones such as glucagon, thyroxin, 
epinephrine and glucocorticoids can suppress delta 5 and delta 6 desaturase 
enzymes, in contrast to insulin, which is considered a good stimulator of these 
enzymes (Nakamura et al., 1994). Although LA, ALA and their derivatives are 
vital cellular membrane components, mammalian cells are unable to synthesise 
or to convert omega 6 to omega 3 due to the lack of omega 3 desaturase 
enzymes (Simopoulos, 2008). 
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Figure 1.5: Metabolism of Omega 6 & 3 fatty acids. Essential linoleic acid and 
alpha-Linolenic acid cannot be synthesised in the human body and must be 
obtained from diet. Delta 6-Desaturase is the rate limiting enzyme in this pathway. 
Both fatty acids are metabolised via a series of desaturation (double bond 
addition) and elongation (two carbon atoms addition) reactions to longer 
derivatives.  
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1.5 Role of omega 6 and 3 in NAFLD development 
DHA, EPA and AA are all incorporated into lipid bilayers of cell membranes, with 
changes in the proportions of these fatty acids affecting membrane fluidity 
(Candela et al., 2011; Patterson et al., 2012). Patterson et al. (2012) mentioned 
that the lack of ELOVL 5 enzyme leads to the accumulation of ALA and LA 
derivatives (γ-linolenic acid [18:3]) and consequently causes a decrease in the 
production of AA (omega 6), EPA and DHA (omega 3). The accumulation of LA 
derivatives results in the activation of the SRBP1c transcriptional factor, which is 
known to stimulate the synthesis of lipid and be associated with the development 
of liver steatosis. It has also been demonstrated that both delta-6 and delta-5 
desaturase enzymes have low activity in the liver of NAFLD patients with obesity 
(Araya et al., 2010). 
Therefore, the inadequate intake of dietary omega 3 (ALA) or any defect in the 
desaturation and elongation enzymes, as well as an imbalance with omega 6 
linoleic acid, will affect the metabolism of omega 3 and decrease the production 
of DHA and EPA (Simopoulos, 2003). All of these factors increase the ratio of 
omega 6/3 and, as mentioned earlier, upregulate the transcriptional factor 
SREBP1c, which, in turn, activates some lipogenic genes involved in the 
synthesis of fatty acids, such as SCD1 and FAS (Yahagi et al., 2002). In the 
meantime, PPAR will be downregulated and supresses the oxidation of fatty acids 
and consequently deactivates the transcription of some genes involved in the 
degradation of fatty acids, such as acyl-CoA oxidase and carnitine palmitoyl 
transferase-1 in the mitochondria. These changes will then stimulate the 
accumulation of TG in the liver and result in the development of NAFLD (Figure. 
1.6) (Kersten et al., 1999; Levy et al., 2004; El-Badry et al., 2007). 
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The recommended ratio of omega 6/3 is 1:1 to 2-4:1. Currently, omega 6 is more 
highly consumed in Western societies than omega 3, reflecting a higher ratio of 
omega 6/3 (20-30:1) one that is considerably greater than the recommended ratio 
(Candela et al., 2011). This imbalance can be normalised through increasing the 
dietary consumption of EPA and DHA, which will then to a certain extent replace 
excess omega 6 fatty acids, especially AA, in the cellular membrane of 
hepatocytes, erythrocytes, platelets, neutrophils and monocytes (Simopoulos, 
2003).  Indeed, by increasing the omega 6/3 ratio, eicosanoid metabolites will be 
largely produced from AA rather than from EPA. Eicosanoids are metabolic 
products of omega 6 and 3; they include thromboxanes, prostaglandins, lipoxins, 
leukotrienes and hydroxy fatty acids. Small amounts of eicosanoids have 
important biological roles; however, large quantities of these products produced 
from AA by the high consumption of omega 6 will act as a pro-inflammatory 
molecule, thus contributing to many inflammatory diseases, such as NAFLD. 
Meanwhile, EPA and DHA eicosanoid products have an anti-inflammatory effect 
that can antagonise the effect of the pro-inflammatory eicosanoids produced from 
AA (Rustichelli et al., 2009; Simopoulos, 2008; Patterson et al., 2012). Indeed, 
the low level of omega 3, which occurs in the hepatic tissue of NAFLD, reflects 
the trend of fatty acids towards fatty acid storage in the form of triacylglycerol and 
lipogenesis, instead of undergoing ß-oxidation. Thus, a high omega 6/3 ratio 
contributes to the development of NAFLD due to the derangement of the liver to 
handle and metabolise lipids (Araya et al., 2004; Patterson et al., 2012).  
 
Omega 6 and 3 play crucial roles in cell signalling as well as in gene expression 
(Patterson et al., 2012). Therefore, dietary omega 6/3 ratio imbalance contributes 
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to the pathogenesis of many diseases, such as hypertension, coronary disease, 
arthritis and diabetes (Candela et al., 2011; Simopoulos, 2008). However, few 
studies have examined the exact ratio of omega 6/3 that can be implicated in the 
pathogenesis of NAFLD. Whether an increased omega 6/3 ratio could enhance 
mitochondrial dysfunction is yet to be determined. Also, what roles could 
cannabinoids play in the development of NAFLD? This warrants further 
investigation into such mechanisms involved in the pathogenies of NAFLD. 
 
1.6 Alcoholic liver disease (ALD) 
Heavy and prolonged alcohol consumption plays a major role in the prevalence 
of alcoholic liver disease (ALD) and many other diseases, such as some 
malignant neoplasm and heart diseases in Western countries (Popova et al., 
2007). ALD has different stages; hepatic steatosis is the first stage, arising in 90% 
of alcohol consumers in response to heavy alcohol consumption (Arteel et al., 
2003; Méndez-Sánchez et al., 2005). Although this stage is reversible and 
asymptomatic, the continued intake of alcohol causes 20-30% of cases with 
simple steatosis to evolve into alcoholic steatohepatitis, which is characterised by 
inflammation and fibrosis. This can then develop into cirrhosis, an irreversible 
stage (in 16% of patients). It may later develop into hepatocarcinoma (Figure 1.7) 
(Deleuran et al., 2012; Pateria et al., 2013; Nassir and Ibdah, 2014). Similarly to 
NAFLD, the pathogenesis of ALD is still not fully understood, reflecting the urgent 
need for further investigation into the mechanisms involved in the development 
of ALD.  
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Figure 1.7: Pathogenesis of alcoholic liver disease and percentage among heavy 
drinkers. 
 
About 76 million out of two billion people worldwide, who regularly consume 
alcohol at the rate of an average of 13 g/day, are diagnosed with disorders 
involving alcohol use. It also has been found that a high average rate of 
consumption of alcohol in England is highly associated with 200 conditions 
ranging from acute and chronic, such as cardiovascular diseases and cancers. 
Treating them comes at an estimated cost of £2.7 billion of the direct annual 
health care expenditure by the National Health Services in the United Kingdom 
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(UK), which soared to £3.5 billion between 2011 and 2012 (British Medical 
Association Board of Science, 2008; Gao and Bataller, 2011; Waszkiewicz et al., 
2012; Knott et al., 2015). 
  
As indicated in a report that WHO published in 2011 on alcohol and health, 
around 4.5% of the global burden of injury and disease was correlated to alcohol 
consumption, with the rates being about 7.4% and 1.4% for males and females, 
respectively. Beer, wine and spirits are the most commonly consumed types of 
alcohol, in ascending order. Regardless of the type of alcohol drink consumed, 
ALD is considered the prime cause of chronic liver disease and has a central 
causative role leading to increased mortality rates worldwide due to its ability to 
develop into fibrosis and cirrhosis. In 2004, around 3.8% of all deaths were 
related to alcohol consumption. According to a report published by the National 
Institute of Alcohol Abuse and Alcoholism, liver cirrhosis was ranked as the 12th 
major cause of mortality in the United States with a total death number of 29,925 
in 2007, with 48% of this number being correlated to alcohol use (Gao and 
Bataller, 2011; Waszkiewicz et al., 2012). 
 
It seems that alcohol intake elevates with urbanisation and industrialisation of the 
country. As the WHO stated, consumers in Eastern Europe are the biggest 
alcohol consumers in the world; there, the average of pure alcohol intake per 
capita is 12.2 L/year, whereas the eastern region of the Mediterranean and the 
Middle East showed the lowest percentages with an average of 0.7 L/year/capita 
(Roswall and Weiderpass, 2015). 
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1.7 Alcohol metabolism 
Alcohol is an organic compound that can be metabolised in the body by two 
different pathways: oxidative and non-oxidative. Oxidative alcohol metabolism 
occurs mainly in the liver, in the cytosol of the hepatocyte. In this pathway, alcohol 
is metabolised by an enzyme called alcohol dehydrogenase (ADH) into 
acetaldehyde, which is considered a highly toxic and reactive molecule and is 
accompanied by NAD reduction into NADH. Other enzymes are also involved in 
the oxidation of alcohol, such as the microsomal ethanol oxidising system 
(MEOS), known as cytochrome P450 isoenzymes. Cytochrome P450 comprises 
a group of enzymes that includes CYP2E1, 3A4 and 1A2, and it is predominantly 
found in the endoplasmic reticulum and contributes to alcohol metabolism. 
Generally, with chronic alcohol consumption and/or when the concentration of 
alcohol is elevated, CYP2E1 is induced, resulting in oxidising the excessive 
amount of alcohol to acetaldehyde as well as generating ROS, which contributes 
to ER stress (Ji, 2008; Leung and Nieto, 2013). Catalase, another enzyme 
located in the peroxisomes, plays a minor role in metabolising ethanol to 
acetaldehyde. Finally, acetaldehyde oxidation occurs in the mitochondria through 
the enzyme aldehyde dehydrogenase (ALDH2), which has the highest affinity to 
acetaldehyde among the 19 ALDH mammalian genes, producing acetate and 
another NADH molecule, which, in turn, can be oxidised by the mitochondrial 
ETC (Lemasters, et al., 2012; Waszkiewicz et al., 2012; Zakhari, 2013). On the 
other hand, acetate is released into the bloodstream and can thus be metabolised 
further by peripheral tissues to form carbon dioxide, water or fatty acids (Figure 
1.8) (Caballería, 2003).  
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Figure 1.8: Oxidative alcohol metabolism. Alcohol is mainly metabolised into 
acetaldehyde by alcohol dehydrogenase (ADH) in the cytoplasm and the 
microsomal cytochrome P450 2E1 (CYP2E1) in the endoplasmic reticulum. 
However, to minor extent, alcohol also converted in the peroxisomes by catalase 
to acetaldehyde with a production of H2O. Acetaldehyde then metabolised into 
acetate by the mitochondrial acetaldehyde dehydrogenase (ALDH). NAD, 
nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine 
dinucleotide; H2O2, hydrogen peroxide; NADPH, reduced nicotinamide adenine 
dinucleotide phosphate; NADP, nicotinamide adenine dinucleotide phosphate. 
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Non-oxidative ethanol metabolism is mediated by the esterification of ethanol and 
fatty acids or fatty acyl-CoA into fatty acid ethyl esters (FAEE). Non-oxidative 
ethanol metabolism oxidises only about 1% of ethanol by FAEE synthase 
enzymes found in the cytosol and microsomes of the liver, pancreas, heart and 
brain. These organs can easily be damaged by ethanol and its non-oxidative 
(FAEE) metabolite, as well as oxidative metabolites (acetaldehyde) and 
generated ROS. FAEE can destabilise the cellular and lysosomal membranes by 
increasing the fluidity of the membrane, consequently leading to mitochondrial 
oxidative phosphorylation uncoupling in the ETC followed by a reduction in the 
ATP produced (Table 1.2) (Waszkiewicz et al., 2012). 
 
Alcohol metabolism can exert a significant fluctuation and elevation in the ratio of 
NADH/NAD through the production of acetaldehyde and acetic acid, causing an 
extravagant reduction in the level of the nicotinamid adenine dinucliotide (NAD). 
Under normal conditions, the approximate ratios of NADH/NAD in the hepatic 
cytosol and mitochondria are 700:1 and 7–8:1, respectively. However, chronic 
alcohol consumption leads to an elevation of this ratio and disturbs the 
metabolism of several pathways, such as carbohydrate, uric acid, lipids and 
protein metabolism. Elevated NADH/NAD ratios also influence the modulation of 
gene expression, cell death and mitochondrial permeability transition opening 
(MPT); the latter leads to mitochondrial swelling, loss of the mitochondrial 
membrane potential and subsequently reduced adenosine triphosphate (ATP) 
synthesis (Table 1.2). Acute or chronic alcohol consumption can increase the 
availability of NADH, which drives the mitochondrial ETC, leading to increased 
electron leakage at complexes I and III and a subsequent elevation in ROS 
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formation (Cunningham and Bailey, 2001; Waszkiewicz et al., 2012; Zakhari, 
2013). 
 
The formation of ROS, which is mediated by the CYP2E1 isoenzyme, is also 
generated by various reactions, such as lipid metabolism and NADPH oxidase; 
however, the majority is via the mitochondrial ETC (Waszkiewicz et al., 2012; 
Leung et al., 2013; Zakhari, 2013). Epigenetic changes caused by oxidative 
alcohol metabolism can be induced by several mechanisms, such as high 
NADH/NAD ratio and via the production of acetate, acetaldehyde and ROS 
(Zakhari, 2013). However, due to the electrophilic nature of acetaldehyde, it can 
covalently bind to molecules, such as protein, lipids and DNA, changing the 
homeostasis of the cell by altering the protein structure and promoting DNA 
mutations as well as inducing ER stress (Table 1.2) (Ceni et al., 2014; Ji, 2015). 
 
Deduced from what has been discussed on alcohol metabolism, alcohol 
metabolites (acetaldehyde, acetate, FAEE) are all involved in the pathogenesis 
of ALD due to their harmful impact on the cellular haemostasis. There are also 
studies pointed at the role of fatty acids in the pathogenesis of ALD and how the 
amount and the type of fatty acids are involved in alcoholic liver injury (Tsukamoto 
et al., 1986; Nanji and Hiller-Sturmhofel., 1997; Caro and Cederbaum., 2007). In 
addition, increasing the ratio of NADH/NAD and the production of ROS, which, in 
turn, increases either the mitochondrial oxidative stress or ER stress, are all 
engaged in distracting the mechanisms involved in ALD.   
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Table 1.2: Key molecular alterations following alcohol metabolism 
Metabolite or 
Molecule 
Mechanism Effect 
Acetaldehyde 
Binding to membrane protein, 
DNA or lipid 
Changing the fluidity of the 
membrane by changing the 
cellular homeostasis 
Inducing ER stress causing 
steatohepatitis 
FAEE 
Causing oxidative 
phosphorylation uncoupling 
ATP synthesis reduction     
Destabilization of the cellular 
membrane 
Increasing the permeability of 
the membrane 
NADH/NAD ratio 
ETC disruption resulting in 
electron leakage and ATP 
synthesis reduction 
Increasing the cellular 
membrane permeability  
ROS 
Production of reactive lipid 
molecules 
Damage the membrane of the 
cell, and change the membrane 
stabilisation. 
 
ER- endoplasmic reticulum; NADH/NAD- nicotinamide adenine dinucleotide 
(reduced/oxidised form); FAEE- fatty acid ethyl ester; ROS- reactive oxygen 
species; ETC- electron transport chain; ATP- adinosin triphosphate. 
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1.8 Aims  
The aim of this project was to investigate the mechanisms involved in fatty liver 
disease development, with particular attention focused on studying the role of 
omega 6/3 ratio in NAFLD pathogenesis, alongside mitochondrial function and 
lipid biogenesis. 
 
1.9 Objectives: 
1. To characterise the effect of fatty acids (saturated/ unsaturated) and omega 3 
and 6 fatty acids ratio on lipotoxicity and lipid accumulation in HepG2 cells 
2. To determine the effect of omega 6/3 ratio on lipid metabolisms and cannabinoid 
system 
3. To investigate the effect of alcohol and omega 6/3 ratio on mitochondrial function   
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2.1 Materials 
Triglyceride Assay Kit was obtained from Universal Biologicals (Cambridge, 
United Kingdom [UK]).  Tumour necrosis factor (TNF-α) was obtained from 
Cayman (Cambridge, UK). Heat-inactivated foetal calf serum (FCS) was obtained 
from Biosera (Ringmer, UK). Phosphate buffered saline (PBS), L-glutamine, 
penicillin-streptomycin mix and Dulbecco’s Modified Eagle Medium (DMEM) were 
obtained from Lonza Ltd (Wokingham, UK). 1x Trypsin in DPBS was from First 
Link Ltd (Birmingham, UK). Sodium pyruvate, thiazolyl blue tetrazolium bromide 
(MTT), Oil red O, 2′,7′-dichlorofluorescin diacetate (DCFDA), palmitic acid (PA), 
stearic acid (SA), linoleic acid (LA), α-Linolenic acid (ALA), arachidonic acid (AA), 
docosahexaenoic acid (DHA) and D-(+)-Glucose were acquired from Sigma-
Aldrich (Gillingham, UK). Dimethyl sulphoxide (DMSO), formaldehyde and 
isopropanol were obtained from Fisher Scientific UK (Loughborough, UK). XF 
Cell Mito Stress Test Kit and Seahorse XF Assay Medium were obtained from 
Agilent Technologies (Craven Arms, UK).   
 
2.2 Methods 
 
2.2.1 Cell culture 
Human hepatoma cell lines VA-13 and VL-17A, which are HepG2 cells that over-
express ADH, and CYP2E1 and ADH respectively, were generously given by Dr. 
Dahn Clemens (University of Nebraska, Nebraska, United States of America 
[USA]). Cells were cultured in a high-glucose (25 mM) DMEM supplemented with 
penicillin (100 u/ml) and streptomycin (100 mg/ml), L-Glutamine (2 mM), 10% 
FCS and sodium pyruvate (1 mM) (Chandrasekaran et al., 2011; Gyamfi et al., 
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2012) at 37ºC in 5% CO2 atmosphere. VL-17A cells were also grown in the 
presence of Plasmocin Prophylatic 5-µg/mL DMEM for the initial four weeks prior 
to their culturing in a high glucose medium. The medium was then changed after 
3–4 days from the seeding day. At a 70% confluence, cells were trypsinised and 
split, then treated with alcohol or various fatty acids (individual or a mixture) with 
a range of different concentrations (Donohue et al, 2006; Gyamfi et al., 2012). 
Briefly, fatty acids were prepared as described by Gyamfi et al. (2012) in DMSO 
as a 8 mM stock. Alcohol or fatty acids were diluted in 1% FCS low-glucose (1 
g/L) DMEM to the required concentrations. Fatty acids were in free form with a 
concentration of 0.02% bovine serum albumin in the FCS. 
 
2.2.2 Determination of cellular lipotoxicity  
2.2.2.1 MTT assay 
Cell viability was assessed by the MTT method with a slight modification 
(Chuturgoon et al., 2015). Either VA-13 or VL-17A cells were seeded overnight 
in a 96-well plate (2.5x104 cells/ 200 µl DMEM per well) and then treated with the 
corresponding concentration of individual saturated fatty acids SA or PA (20, 80, 
160 µM) or individual unsaturated fatty acids LA, ALA, AA or DHA (0.5–300 µM). 
Cells were also treated with a mixture of the fatty acids LA/ALA or AA/DHA at 
various ratios (1:1, 4:1, 15:1 and 25:1 ratio) or a mixture of AA (40 µM) with 
alcohol (100 mM) for six, 24, 48 and 72 h. Vehicle control was included as 0.5% 
DMSO. After 2 h of incubation with MTT (5 mg/ml) at 37ºC, the reagent was 
removed and cells were incubated with DMSO (100 µl/well) for 15 min at room 
temperature. Cell proliferation was then determined by assaying the ability of the 
succinate dehydrogenase enzyme in the mitochondria to reduce the MTT to a 
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blue formazan crystal. This colour intensity was measured at 550 nm using a 
VersaMax microplate reader (Molecular Devices, Wokingham, UK). The data was 
expressed as percentage from the control group. 
 
2.2.3 Determination of steatosis 
2.2.3.1 Oil red O assay 
To quantify the amount of lipid accumulation following fatty acid treatment, cells 
(5x104 cells/well) were seeded and treated in a 96-well plate as described above 
for 24, 48 and 72 h. Cells were then fixed for 1 h with 10% formalin at room 
temperature. After fixation, the cells were washed two times with ice cold PBS 
and stained with 60% oil red solution (3 mg/mL in isopropanol) for another 1 h at 
room temperature. Then, the cells were washed twice for a second time with ice 
cold PBS and once with distilled water then incubated for 5 min with DMSO. Next, 
the absorbance was measured calorimetrically at 510 nm with a VersaMax 
microplate reader (Molecular Devices, Wokingham, UK). The data are reported 
as percentages from the control (Gyamfi et al., 2012). 
 
2.2.3.2 Measurement of intracellular triglyceride content 
The triglyceride content in VL-17A cells was measured using an EnzyChrom 
Triglyceride Assay Kit (BioAssay Systems, USA) (Guo et al., 2011). Briefly, cells 
were seeded at a density of 2 x 105 cell/ 2 mL in a 24-well plate overnight. After 
the cells adhered, the cells were treated in triplicate for 24, 48 and 72 h with four 
different AA/DHA ratios ranging from 1:1 to 25:1 using 1% FCS DMEM, along 
with a vehicle control containing 0.5% DMSO as a final concentration. The 
triglyceride content was then determined following the manufacturer’s 
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instructions after the cells had been washed and trypsinised (Gyamfi et al., 2012). 
The protein concentration was also measured using a Bio-Rad protein assay kit 
according to the manufacturer’s instructions. The triglyceride content was 
expressed as milligram triglyceride per milligram protein.   
 
2.2.4 Western blot 
Following treatment as described above with different fatty acid ratios for a 24 h, 
the expression of cannabinoid receptors 1 and 2 (CB1, CB2) and the 
transcriptional factors (sterol regulatory element-binding protein (SREBP1), 
peroxisome proliferator-activated receptor (PPAR-α), Stearoyl-CoA desaturase 
(SCD1)) was determined. VL17A cell pellets were treated with a Protease 
Inhibitor Cocktail (1 ml/108 cells/ml) (Sigma-Aldrich, Gillingham, UK) to avoid the 
degradation of the intact protein by endogenous enzymes, such as phosphatase 
and protease. Cells were then lysed with 1% Triton 100x, and the protein 
concentration was measured using a Bio-Rad protein assay kit by following the 
manufacturer's instructions (Bio-Rad Laboratories, Hemel Hempstead, UK). 
Protein from cell lysate was then prepared by adding 5x SDS Protein Sample 
Buffer containing 30% glycerol, 0.31M Tris, 10% SDS and 0.5% bromo phenol 
blue. Protein (20-40 µg) was loaded on 10% SDS-PAGE gels (Thermo Scientific 
Pierce, UK). The gel was electrophoresed for 90 min at 120 v and then electro-
blotted onto a nitrocellulose membrane (0.45 µm) for 1 h at 350 A. To evaluate 
the transfer quality and the equality of band intensity, the membrane was stained 
with Ponceau S solution before being blocked for 1 h with BSA blocking buffer 
([1%] in 1% 1x Tween-PBS [TPBS] for all antibodies except β-actin with [5%] 
BSA) at room temperature and then washed three times with 1X TPBS prior to 
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being incubated with a primary antibody overnight. An immunoblot analysis of 
proteins was carried out using primary antibodies; these are as follows: mouse 
anti-human SREBP-1 (1:250) (Santa Cruz Biotechnology, Santa Cruz, UK) and 
SCD1 (1:4000) monoclonal antibodies. Rabbit polyclonal antibody recognising 
PPAR alpha (1:2000) and CB2 (1:2000), as well as goat polyclonal antibody 
recognising CB1 (1:4000) (Santa Cruz Biotechnology, Santa Cruz, UK) were 
used.  
 
After the incubation, the membrane was washed three times with 1X TPBS and 
then incubated with rabbit anti-mouse (for actin, SCD1 and SREBP-1), goat anti-
rabbit (for PPARα and CB2) and rabbit anti-goat (for CB1) IgG peroxidase as a 
secondary antibody for 1h at room temperature (Table 2.1). Bands were imaged 
on x-ray film after the membrane was incubated with West PICO 
Chemiluminescent Substrate (ThermoFisher, Cramlington, UK) and normalised 
to actin (Patel et al., 2007). All films were scanned by a Bio-Rad GS-800 
Calibrated Densitometer (Bio-Rad, Hemel Hempstead, UK). Secondary 
antibodies were all obtained from Sigma Aldrich, (Gillingham, UK). Primary 
antibodies SCD1, CB2, PPAR alpha and β-actin antibodies were purchased from 
Abcam (Cambridge, UK). 
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Table 2.1 Concentrations of optimised primary and secondary antibodies  
                Concentration 
Antibody 
Primary antibody Secondary antibody 
SREBP1 1:250  1:2000 
PPAR-α 1:2000 1:4000 
SCD1 1:4000 1:10000 
CB1 1:750                                                               1:2000 
CB2 1:2000 1:8000 
 
 
2.2.5 Determination of ROS  
The level of intracellular ROS was investigated in VL-17A cells by using DCFDA. 
Briefly, the cells were seeded at a concentration of 1 or 5 x 104 cell/ 200-µl DMEM 
in a 96-well plate at 37ºC for an overnight period. The cells were then treated 
separately with either different omega 6/3 ratios (1:1–25:1) or a mixture of alcohol 
(100 mM) and omega 6/3 ratios (1:1–25:1) for 30 min–2 h. Following the 
incubation, the cells were incubated with 1 µM DCFDA diluted in PBS for 45 min 
at 37ºC. The intensity of fluorescence was determined by FLUOstar OPTIMA 
(Jencons-PLS, Bedfordshire, UK) at an excitation of 485 nm and an emission of 
535 nm. The intracellular ROS level was indicated by the fluorescence level, and 
the results are expressed as percentage from the control. 
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2.2.6 Measurement of mitochondrial stress 
To evaluate the mitochondrial respiration rate, an XF Cell Mito Stress Test Kit 
was used following the manufacturer’s instructions. In brief, VL-17A cells were 
seeded on SeaHorse 24-well cell culture microplates (Agilent Technologies, 
Craven Arms, UK) at a density of 1.5 x 104 cells/100µL (10% FCS) DMEM and 
were incubated at 37ºC, 5% CO2. After two hours of adherence, 150 µL of DMEM 
(10% FCS) was added to the cultured cells and re-incubated for an overnight 
period, then treated for 24 h with 500 µL per well of 10% FCS DMEM containing 
4 different ratios of omega 6/3 (1:1 to 25:1) along with a vehicle control containing 
(0.5% DMSO). On the day of treatment, 1 mL per well of XF Calibrant Solution 
(Agilent Technologies, Craven Arms, UK) was added into the 24-well SeaHorse 
Utility Plate topped with a SeaHorse Sensor Cartridge (Agilent Technologies, 
Craven Arms, UK) and dehydrated overnight at 37ºC with 0% CO2 atmosphere. 
Following the incubation, Seahorse XF Assay Medium without glucose was 
augmented with 25 mM of glucose and sodium pyruvate (1 mM) and adjusted at 
pH 7.4. Next, cells were washed twice with 500 µL of the above prepared 
SeaHorse XF medium then incubated with 500 µL SeaHorse medium for 45 min 
at 37ºC without CO2 to de-gas and to allow CO2 diffusion from the cells and 
medium. The oxygen consumption rate of the cells was then monitored using a 
SeaHorse XF analyser (Agilent Technologies, Craven Arms, UK) after being 
calibrated with the sensor cartridge containing Mito stress drugs—oligomycin (1 
µM) to inhibit ATP synthase; FCCP (1 µM), an uncoupling agent; and an 
antimycin/Rotenone mixture (0.5 µM)—to inhibit oxidative phosphorylation and 
electron transfer, respectively. Seahorse cell Mito stress parameters were 
calculated following manufacture’s protocol as outlined below (Table 2.2) (Figure 
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2.1). following OCR measurement, cells were lysed using 1% Triton X-100 and 
protein content was measured using Bio-Rad protein assay kit for normalisation. 
The data are expressed as percentages from the control. 
     
Table 2.2: Calculations of Seahorse cell Mito stress test parameters 
Parameters  Equations 
Non-mitochondrial 
respiration 
Minimum measurement following Rotenone/Antimycin 
injection   
Basal respiration  (Average of measurements before Oligomycin injection) 
_ (Non-mitochondrial respiration) 
Maximal respiration (Highest rate measurement after FCCP injection) _ 
(Non-mitochondrial respiration) 
Proton (H +) leak  (Lowest rate measurement after Oligomycin injection) _ 
(Non-mitochondrial respiration) 
ATP production (average rate measurement prior Oligomycin injection) 
_ (lowest rate measurement after Oligomycin injection)   
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Figure 2.1: Seahorse Mito stress test parameters. Source: For more information 
on Agilent Seahorse XF cells Mito stress parameters and kinetics see 
http://www.agilent.com/en-us/products/cell-analysis-(seahorse)/xf-cell-mito-
stress-test-report-generator 
 
2.2.7 Liver function test and TNF-α cytokine measurements in ALD patients 
Liver function profile in alcoholic patients includes the following tests: Bilirubin, 
aspartate transaminase (AST), alanine transaminase (ALT), alkaline 
phosphatase (ALP), Gamma Glutamyltransaminase (GGT), albumin and total 
protein. These were kindly measured in the serum of normal individuals (n= 15) 
and alcoholic patients (IRAS project ID 135979) (n= 63) by Dr. Vinood Patel using 
an Ilab Aries Clinical chemistry analyser. 
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TNFα inflammatory cytokine was measured using TNFα (human) EIA Kits 
following manufacture’s protocol. Briefly, serum was incubated with 
acetylcholinesterase:Fab’ conjugate for overnight at 4ºC in a 96-well plate coated 
with  monoclonal antibody specific for TNFα to bind TNFα in the well. Next day, 
wells were washed five times with a washing buffer then incubated for 2 h in the 
dark with EIIman’s reagent. Colour intensity was measured 
spectrophotometrically by FLUOstar OPTIMA (Jencons-PLS, Bedfordshire, UK) 
at 410 nm and cytokine concentration was expressed as pg/mL.  
 
2.2.8 Statistical analysis 
SPSS version 23.0 was used to perform one-way ANOVA to analyse the data, 
followed by post hoc multiple comparisons using Tukey’s test. The data are 
reported as the mean ± standard error of mean (SEM), and the differences were 
considered significant if the p value ≤ 0.05. 
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Chapter 3 
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3. Results 
The first series of experiments involved determining the comparative effect of 
different types of fatty acids, saturated, unsaturated and mixture of fatty acids, as 
well as studying the concentration and period of treatment on cell viability and 
lipid accumulation.  
 
3.1 Effect of saturated palmitic acid on cell viability and steatosis:  
Palmitic acid is a C16 saturated fatty acid that has previously been reported to 
induce fatty liver and lipotoxicity (Wang et al., 2006; Oh et al., 2012). To confirm 
whether similar effects were observed in VA-13 cells and that this cell line could 
be used as a model of NAFLD, cell viability was assessed using the MTT assay 
after treating the cells with different palmitic acid concentrations (20, 80, and 160 
µM) for 24, 48, and 72 h. The results showed that increasing the concentration 
and incubation time of palmitic acid (PA) treatment led to increasing cell death, 
especially at 80 and 160 µM, at these time points. The 160 µM treatment caused 
a significantly greater drop (-59% at 24 h and -53% at 48 h) in cell viability than 
the 80 µM treatment (-35% at 24 h and -34% at 48 h) (P < 0.001) when compared 
to control. There was further reduction in the cell viability with the 160 µM 
treatment at 72 h (-62%, P < 0.001) when compared to control at 72 h (Figure 
3.1A-C). 
 
With increasing concentration and incubation time PA treatment significantly led 
to an increase in lipid accumulation. After 24 h of 80 µM palmitic acid treatment, 
lipid accumulation was slightly elevated by 17%, whereas the increase at 160 µM 
(24%) was significantly higher (P < 0.05) than the control (Figure 3.1D). At 48 h, 
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lipid accumulation correlated closely to higher palmitic acid concentrations when 
compared to control, where 20 µM, (28%, P < 0.05;) 80 µM (39%, P < 0.01) and 
at 160 µM (96%, P < 0.001) (Figure 3.1E). After 72 h a similar pattern was 
observed, whereby increasing palmitic acid concentration was accompanied by 
an increase in lipid accumulation with a 16% increase at 20 µM (P>0.05), +45% 
at 80 µM and +55% at 160 µM when compared to the control (P < 0.05) (Figure 
3.1F). However, among all time points, lipid accumulation was most apparent 
after 48 h than at other time points. 
  
  
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Effect of palmitic acid on the viability of VA-13 cells (A-C) and 
lipid accumulation (D-F) after 24, 48, and 72 h. The results are presented as 
mean ± SEM (n = 3 determinations of 6 replicates per treatment). *P < 0.05, **P 
< 0.01, and ***P < 0.001 as compared to the control. PA, Palmitic acid.  
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3.2 Effect of saturated stearic acid on cell viability and steatosis: 
The viability of the cells was also assessed after treatment with three different 
concentrations of the saturated C:18 fatty acid stearic acid (20, 80, and 160 µM) 
for 24, 48, and 72 h. In contrast to PA, after 24 and 48 h of treatment, the 20 µM 
and 80 µM stearic acid treatment had no effect on cell viability (P > 0.05). 
However, the 160 µM treatment caused a large drop in cell viability (by -48% and 
-36% after 24 and 48 h, respectively) (P < 0.01) (Figure 3.2A, B). The effect at 72 
h was considerably greater where cell viability gradually decreased at higher 
concentrations when compared to the control (-23% at 20 µM, -44% at 80 µM 
and -67% at 160 µM; P < 0.001) (Figure 3.2C).  
 
Again, in contrast to PA treatment, neither increasing the exposure time nor 
raising the concentration of stearic acid caused any change in lipid accumulation 
(P > 0.05) (Figure 3.2D-F). 
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Figure 3.2: Effect of stearic acid on the viability of VA-13 cells & lipid 
accumulation after 24, 48, and 72 h. The results are presented as mean ± SEM 
(n = 3 determinations of 6 replicates per treatment). *P < 0.01 and **P < 0.001 as 
compared to the control. SA, Stearic acid. 
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3.3 Effect of unsaturated omega 6 linoleic acid on cell viability and 
steatosis:  
As discussed in section 1.5, omega 6 fatty acids are thought to be detrimental to 
liver function leading to the development of NALFD.  However, less information 
is known about the precursors to AA.  Here, cell viability was analysed after 
treatment with various concentrations of omega 6 linoleic acid (LA) (10, 30, 50, 
100, 200, and 300 µM) at 24, 48 and 72 h. At 24 h, compared to that in the control, 
cell viability at 200 µM dropped significantly (-37%; P < 0.001) and further 
decreased at 300 µM (-48%; P < 0.001) (Figure 3.3A). A lower decline was 
observed at 48 h with 300 µM (-22%; P < 0.05), while after 72 h, there was a 
significant drop in the 200 µM group (-30%) than in the 50 µM and 100 µM groups 
(-28%) (P < 0.05) (Figure 3.3B, C).  
 
Treating the cells with omega 6 LA (10-300 µM) for 24, 48, and 72 h did not show 
any statistically significant increase in lipid accumulation. Although there was a 
slight increase in lipid accumulation after 48 and 72 h, this increase was not 
significant compared to the control (P > 0.05) (Figure 3.3D-F). 
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Figure 3.3: Effect of linoleic acid on the viability of VA-13 cells & lipid 
accumulation after 24, 48, and 72 h. The results are presented as mean ± SEM 
(n = 4 determinations of 6 replicates per treatment). *P < 0.001 as compared to the 
control; **P < 0.05 as compared to the value at 50 µM; ***P < 0.05 as compared to 
the value at 200 µM; # P < 0.05 as compared to the value at 300 µM. LA, linoleic 
acid.  
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3.4 Effect of unsaturated omega 6 arachidonic acid on cell viability and 
steatosis:  
Cell viability was analysed after treatment with various concentrations of omega 
6 arachidonic acid (AA) (10, 20, 30, and 80 µM) for 24, 48, and 72 h. 80 µM 
treatment caused a significant decrease in cell viability after 24 and 48 h (-21%, 
P < 0.05 and -20% P < 0.01, respectively) (Figure 3.4A, B).  However, at 72 h, 
there was a gradual, significant reduction at 20 µM (-18%; P < 0.05) followed by 
a significant gross reduction of 69% at 30 µM and 96% at 80 µM (Figure 3.4A-C).  
 
No significant change was observed after 24 h of treatment in lipid accumulation. 
However, after 48 h, the 30 µM and 80 µM AA treatments caused a 37% and 
40% (P < 0.05) increase in lipid accumulation, respectively. However, after 72 h, 
this effect was reversed, whereby at 10 µM and 20 µM lipid accumulation was 
reduced by -21% and -41%, respectively (P < 0.01), and similarly at 30 µM and 
80 µM AA (-36% and -43%, respectively, P < 0.01). (Figure 3.4D-F). 
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Figure 3.4: Effect of arachidonic acid on the viability of  VL-17A cells & lipid 
accumulation after 24, 48, and 72 h. The results are presented as mean ± SEM 
(n = 3 determinations of 6 replicates per treatment). *P < 0.05, **P < 0.01, and 
***P < 0.001 as compared to the control. AA, arachidonic acid. 
  
57 
 
3.5 Effect of unsaturated omega 3 α-linolenic acid and docosahexaenoic 1 
acid on cell viability and steatosis: 2 
To ascertain the effects of omega 3 fatty acids, α-linolenic acid (ALA) (0.4, 0.66, 3 
1, 2.5, 5, and 10 µM) and docosahexaenoic acid (DHA) (1.2, 2, 3, 7.5, 15, and 30 4 
µM) were used separately at a range of concentrations to study cell viability and 5 
lipid accumulation at 24, 48, and 72 h (Figure 3.5). Cell viability was not affected 6 
by an increase in the ALA concentration at any time point. (Figure 3.5A-C). ALA 7 
treatments also did not show any marked change in lipid accumulation. Although 8 
there was a slight increase at 10 µM (21%), this change was not significant when 9 
compared to the control (P > 0.05) (Figure 3.5D-F).  10 
 11 
In addition, neither increasing the incubation time nor raising the concentration of 12 
DHA had any significant effect on cell viability (Figure 3.6A-C) or lipid 13 
accumulation when compared to the control (P > 0.05) (Figure 3.6D-F).  14 
 15 
  16 
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 17 
 Figure 3.5: Effect of alpha linolenic acid on the viability of VA-13 cells & 18 
lipid accumulation after 24, 48, and 72 h. The results are presented as mean 19 
± SEM (n = 3 determinations of 6 replicates per treatment). P > 0.05 as compared 20 
to the control. ALA, alpha linolenic acid. 21 
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 22 
Figure 3.6: Effect of docosahexaenoic acid (DHA) on cell viability & lipid 23 
accumulation in VL-17A cells after 24, 48, and 72 h. The results are presented 24 
as mean ± SEM (n = 3 determinations of 6 replicates per treatment). P > 0.05 as 25 
compared to the control.   26 
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3.6 Effect of increasing omega LA/ALA (6/3) ratio on cell viability and lipid 27 
accumulation: 28 
As previously discussed (1.5) increased omega 6/3 ratios are associated with the 29 
development of NAFLD. To study the effect of treating VA-13 cells with different 30 
LA/ALA ratios (range 1:1–25:1) on the cell viability, cells were incubated at 31 
various concentrations (1.2–30 µM) for 24, 48, and 72 h. Cell viability did not 32 
change significantly at any ratios after 24 h. However, after 48 h, cell viability 33 
dropped when the ratio increased to 15:1 (-25%) and 25:1 (-22%), while these 34 
reductions were not statistically significant compared to the control, they were 35 
lower when comparing these ratios to 1:1 (-42%, -39%, P<0.05, respectively) and 36 
when comparing the 15:1 ratio to 2:1 ratio (-39%, P= 0.05) (Figure 3.7A,B). After 37 
72 h, increasing the LA/ALA ratio decreased the cell viability; 32% decrease was 38 
observed with 10:1 and 31% with 15:1 (P = 0.08 and P = 0.05, respectively) 39 
(Figure 3.7C).  40 
 41 
To evaluate the effect of an increase in the LA/ALA ratio on lipid accumulation, 42 
cells were treated (as before) with six different ratios, ranging from 1:1 to 25:1 for 43 
24, 48, and 72 h. Steatosis was not observed after 24 h; however, there was a 44 
non-significant reduction in lipid accumulation at 1:1 (-20%), 2:1 (-23%), 4:1 (-45 
24%), and 15:1 (-23%); however, higher high ratios (10:1 and 25:1) did not cause 46 
any change. Increasing the incubation period to 48 h increased the lipid 47 
accumulation at 15:1 and 25:1 by 13% and 16%, respectively, compared to the 48 
control (P>0.05). The 72 h exposure treatments also failed to increase lipid 49 
accumulation (Figure 3.7 D-F). 50 
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 51 
 52 
 53 
Figure 3.7: Effect of treatment with different concentrations of the LA/ALA 54 
ratio on cell viability & lipid accumulation in VA-13 cells after 24, 48, and 72 55 
h. The results are presented as mean ± SEM (n = 3-5 determinations of 6 56 
replicates per treatment) *P < 0.05 as compared to the value with the 1:1 ratio; 57 
#P < 0.05 as compared to the value with the 2:1 ratio. LA, Linoleic acid. ALA, 58 
alpha linolenic acid.  59 
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3.7 Effect of increasing the omega 6/3 (AA/DHA) ratio on cell viability and 60 
steatosis: 61 
Cells were treated with different ratios of both, AA and DHA (range: 1:1–25:1) for 62 
24, 48, and 72 h. Data showed that increasing the ratio of AA/DHA (omega 6/3), 63 
had a significant negative effect on cell viability. High ratios (15:1 and 25:1) of 64 
AA/DHA significantly reduced cell viability. After 24 h, a ratio of 15:1 caused a 65 
17% reduction in cell viability (P < 0.05), which increased considerably at 25:1 66 
where the reduction was 82% (P < 0.001) when compared to the control. 67 
Interestingly, when compared to 1:1 and 4:1 the viability was still low at 15:1 (-68 
23%, P < 0.01 and -21%, P < 0.05, respectively) and at 25:1 (-88% and 86%, 69 
respectively, P < 0.001). 70 
 71 
At 48 h, only the 25:1 ratio caused a significant reduction in cell viability (-51%, -72 
51%, -57%; P < 0.001) as compared to the control, 1:1, and 4:1, respectively 73 
(Figure 3.8A-C). At 72 h a marked reduction in viability occurred with 15:1 and 74 
25:1 ratio treatment (-91%, P < 0.001 and 89%, P < 0.001, respectively) as 75 
compared to the control. Furthermore, cell viability considerably dropped at 15:1 76 
and 25:1 (-104% and -102%, P < 0.001, respectively) when compared to that at 77 
1:1, with similar effects when 15:1 and 25:1 ratio was compared to 4:1 (-87%, -78 
82%, P < 0.001, respectively).  79 
 80 
Increasing the ratio of AA/DHA (omega 6/3) slightly increased lipid accumulation 81 
at 24 h with 15:1 and 25:1 ratios, with no effect at 48 h (Figure 3.8D-E). In 82 
contrast, lipid accumulation decreased significantly at all ratios at 72 h, with 83 
greatest reductions -32% at 15:1 (P < 0.01) and -53% at 25:1 (P < 0.001) (Figure 84 
3.8F).  85 
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To obtain a second method for determining steatosis, the TG concentration was 86 
quantified per mg protein of cell lysate. This more accurately compensates for 87 
any changes in the cell density which may be affected by the treatment conditions 88 
and/or rapid cell death.  89 
 90 
TG level was measured after treating VL-17A cells with different omega 6/3 ratio 91 
(AA/DHA) for 24, 48 and 72h. Data showed a slight decrease (-12%) in lipid level 92 
after 24h with 15:1 ratio while there was a significant rise (42%; P< 0.01) with 93 
25:1 compared to control. On the other hand, 1:1 ratio indicated a significant 94 
reduction (-43%, P< 0.01) in the level of lipid but 4:1 did not show any change 95 
(1%, P> 0.05) after 24h. Comparing all ratios to 1:1, there was a pronounced 96 
increase in the level of TG with 4:1 ratio (75%, P< 0.01) where this increase 97 
rocketed to 248% (P< 0.001) at 25:1 ratio. This effect decreased although the 98 
level of lipid was still high (53%, P> 0.05) at 15:1 compared to 1:1 ratio (Figure 99 
3.9A). 100 
 101 
After 48h, results indicated a gradual increase in the concentration of TG with a 102 
significant effect at 4:1 and 15:1, (117%, P< 0.05 and 177%, P< 0.01, 103 
respectively) whereas 25:1 ratio showed less significant increase in lipid level 104 
(91%, P< 0.05) (Figure 3.9B). When compared to 1:1 ratio, there was also a 105 
significant elevation in lipid concentration at 4:1 and 15:1 only (91% and 143%, 106 
P< 0.01, respectively). On the other hand, 25:1 ratio showed a significant 107 
increase (68%, P< 0.05) compared to 1:1 ratio and showed a rapid decline in TG 108 
concentration compared to 15:1 (-31%, P= 0.05) (Figure 3.9B). After 72h, lipid 109 
concentration decreased most with 15:1 (-31%, P> 0.05) ratio when compared to 110 
  
64 
 
the control, while all other ratios showed a slight decrease (P> 0.05) (Figure 111 
3.9C). 112 
 113 
 114 
 115 
 116 
 117 
 118 
 119 
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 120 
 121 
Figure 3.8: Effect of treatment with different concentrations of AA/DHA 122 
ratios on cell viability & lipid accumulation in VL-17A cells after 24, 48, and 123 
72 h. The results are presented as mean ± SEM (n = 3 determinations of 6 124 
replicates per treatment). *P < 0.01; **P < 0.001 as compared to the control; #P 125 
< 0.01 and ##P < 0.001 as compared to the value with the 1:1 ratio; ***P < 0.01 126 
and ****P < 0.001 as compared to the value with the 4:1 ratio. AA, arachidonic 127 
acid. DHA, docosahexaenoic acid. 128 
  129 
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 135 
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 144 
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 147 
 148 
 149 
Figure 3.9: Effect of treatment with different concentrations of AA/DHA ratio 150 
on steatosis in VL-17A cells after 24, 48, and 72 h. The results are presented 151 
as mean ± SEM (n = 5 determinations of 3 replicates per treatment), and the 152 
levels of the intracellular TG are expressed as mg/mg protein. *P < 0.01 and 153 
#P<0.05 as compared to the control; ##P<0.05, **P < 0.01 and ***P < 0.001 as 154 
compared to the value with the 1:1 ratio. TG, triglyceride. AA, arachidonic acid. 155 
DHA, docosahexaenoic acid  156 
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3.8 Effect of increasing the omega 6/3 (AA/DHA) ratio on the expression of 157 
PPAR-α, SREBP1, and SCD1: 158 
The expression of key transcriptional genes involved in FA metabolism was 159 
determined using Western blotting after treating VL-17A cells with different 160 
omega AA/DHA ratios ranging from 1:1 to 25:1 for 24 h. The expression of PPAR-161 
α significantly decreased at 15:1 and 25:1 (-29% and -35%, respectively; P < 162 
0.05) in the treated VL-17A cells compared to that in the control. The AA/DHA 163 
ratios caused greater reduction in the PPAR-α expression at 15:1 and 25:1 (-164 
35%; P < 0.05 and -40%; P < 0.01) when compared to that at the 1:1 ratio (Figure 165 
3.10A-B). 166 
 167 
Treating the cells with increasing ratios of AA/DHA for 24 h caused a slight 168 
decrease in the SREBP1 expression at 4:1 and 15:1 (-29% and -16%, 169 
respectively; P > 0.05) when compared to the control. On the other hand, the 170 
SREBP1 expression was significantly decreased only at 4:1 as compared to that 171 
at 1:1 (-35%, P < 0.05). In contrast, at 15:1 and 25:1 ratios, there was non-172 
significant increase in the expression of this gene when compared to that at 4:1 173 
(13% and 21%, respectively; P > 0.05) (Figure 3.11A). SCD1 expression was 174 
assessed using the VL-17A cells treated with various AA/DHA ratios. The SCD1 175 
expression gradually increased with an increase in the AA/DHA ratio. 176 
Interestingly, this elevation was significant at 25:1 as compared to that in the 177 
control, and at the 1:1 and 4:1 ratios (33%, 38%, and 34%; respectively; P < 178 
0.05). However, the increase in SCD1 expression at the 15:1 ratio was not 179 
statistically significant as compared to that in the control, and that at the 1:1 and 180 
4:1 ratios (22%, 27%, and 23%, respectively; P > 0.05) (Figure 3.11B).   181 
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 182 
 183 
Figure 3.10: Effect of increasing AA/DHA ratios on the expression of PPAR 184 
alpha in VL-17A cells after 24 h. A. Immunoblot; B. PPAR/Actin expression. 185 
The results are presented as mean ± SEM (n = 3). *P < 0.05 as compared to B-186 
actin (as a control); **P < 0.05 and *** P < 0.01 as compared to the value with the 187 
1:1 ratio. AA, arachidonic acid. DHA, docosahexaenoic acid.  188 
  189 
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 208 
 209 
Figure 3.11: Effect of AA/DHA ratios (1:1, 4:1, 15:1, and 25:1) on lipogenic 210 
markers (SREBP1 & SCD1) and cannabinoids receptors (CB1 & CB2) in VL-211 
17A cells after 24 hr. A-D. Representative Western blots. E-H. Expression of 212 
proteins relative to beta actin. The results are presented as mean ± SEM (n = 213 
3). *P < 0.05 as compared to the control and 4:1 ratio; **P < 0.05 as compared to 214 
the control, 1:1, and 4:1 ratio. ***P < 0.001 as compared to the control; # P < 0.01, 215 
##P < 0.05 as compared to the value with 1:1 ratio. AA, arachidonic acid. DHA, 216 
docosahexaenoic acid.  217 
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3.9 Effect of increasing the omega AA/DHA ratio on the expression of CB1 218 
and CB2 receptors: 219 
The expression of cannabinoids receptors, CB1 and CB2 were evaluated after 220 
treating the VL-17A cells with increasing omega AA/DHA ratios (range 1:1–25:1) 221 
for 24 h. There was an increase in the CB1 expression with all ratios except 4:1 222 
when compared to that in the control; however, this effect was not statically 223 
significant (17% at 1:1, 11% at 15:1, and 31% at 25:1; P > 0.05) (Figure 3.11C). 224 
 225 
A low expression of CB2 was observed with all ratios in general, and particularly 226 
at the 1:1 ratio (-39%, P < 0.001), with significant decreased CB2 expression at 227 
4:1 (-32%, P<0.001), 15:1 (-26%, P < 0.001) and 25:1 (-17%, P < 0.05) compared 228 
to control. However, compared to 1:1 ratio, the CB2 expression increased slightly 229 
at 4:1, a 13%, (non-significant) increase in the CB2 expression at 15:1, and 230 
interestingly was increased significantly by 22% (P < 0.01) at 25:1 (Figure 3.11D). 231 
 232 
 233 
3.10 Effect of increasing the omega AA/DHA ratio on ROS production: 234 
Increased oxidative stress is a known feature in NAFLD (Seth et al., 2011). 235 
However, no information is known on how high AA/DHA ratios affect ROS. ROS 236 
production was evaluated in the VL-17A cells treated with different omega 237 
AA/DHA ratios (range 1:1–25:1) for 30 min, 1 h, and 2 h. After 30 min, all ratios 238 
caused a significant elevation in the ROS levels (Figure 3.12). The 1:1 and 15:1 239 
ratios increased the ROS levels by 74% (P < 0.05), while the 4:1 and 25:1 ratios 240 
led to an 88% and 104% increase, respectively (P < 0.01) (Figure 3.12A). A 1 h 241 
incubation did not show any significant change in the ROS levels at 1:1 or 4:1 242 
ratios, compared to the control. The 4:1 ratio caused a slight increase in the ROS 243 
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levels (23%, P>0.05). The higher omega ratios, 15:1 and 25:1, caused a marked 244 
increase in the ROS levels. With the 15:1 ratio, ROS levels increased by 117%, 245 
120%, and 93% compared to the control, 1:1 and 4:1, respectively (P < 0.001). 246 
Whereas, the 25:1 ratio caused 96% and 99% (P < 0.001) increase in the ROS 247 
levels compared to that in the control and at 1:1, respectively, and 72% (P < 0.01) 248 
compared to that at 4:1 (Figure 3.12B).  249 
 250 
ROS levels were generally lower at the 2 h time point compared to 30 min and 1 251 
h.  However, ROS production rose significantly by 32% (P < 0.05) and 48% (P < 252 
0.01) at the 15:1 ratio compared to that with the control and 4:1 ratio, respectively. 253 
ROS levels were also moderately increased by 25% at the 25:1 ratio, when 254 
compared to the 4:1 ratio (P < 0.05) (Figure 3.13). 255 
  256 
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Figure 3.12: Effect of increasing AA/DHA ratios on reactive oxygen species 282 
(ROS) production in VL-17A cells at 30 min and 1 h. The results are presented 283 
as mean ± SEM (n = 3 determinations of 6 replicates per treatment). *P < 0.05 284 
and **P < 0.01 as compared to the control; *** P < 0.001 as compared to the 285 
control and the 1:1 and 4:1 ratios; #P < 0.01 as compared to the value with the 286 
4:1 ratio. AA, arachidonic acid. DHA, docosahexaenoic acid. 287 
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Figure 3.13: Effect of increasing AA/DHA ratios on reactive oxygen species 296 
(ROS) production in VL-17A cells at 2 h. The results are presented as mean ± 297 
SEM (n = 3 determinations of 6 replicates per treatment). *P < 0.05 as compared 298 
to the control; **P < 0.05 as compared to the value with 1:1; ##P < 0.01 as 299 
compared to the 4:1 ratio; #P < 0.05 as compared to the value with the 4:1 ratio. 300 
AA, arachidonic acid. DHA, docosahexaenoic acid. 301 
 302 
 303 
3.11 Effect of increasing the AA/DHA ratio on oxygen consumption rate: 304 
Various studies have implicated perturbed mitochondrial function in the 305 
pathogenesis of NAFLD (Gentile and Pagliassotti., 2008; Dowman et al., 2010), 306 
which also can lead onto the more severe stages in disease development. Here, 307 
the respiratory function of the mitochondria was evaluated by measuring the 308 
oxygen consumption rate (OCR) using the Seahorse XF24 analyser after treating 309 
the VL-17A cells with various omega AA/DHA ratios, ranging from 1:1 to 25:1 for 310 
24 h. The results showed that the function of the ETC was affected by an increase 311 
in the omega AA/DHA ratio (Figure 3.14B). Our data showed a gradual, 312 
remarkable decrease in basal respiration with an increase in the AA/DHA ratio. 313 
Thus, basal respiration decreased by 20% (P < 0.05) and 25% (P < 0.01) at 1:1 314 
and 4:1, respectively, and by 38% and 40% at 15:1 and 25:1, respectively, as 315 
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compared to the control (P < 0.001) (Figure 3.15A). Results also indicated 316 
significant reductions in the basal respiration at 15:1 and 25:1 as compared to 317 
1:1 (19% and 21%, respectively, P< 0.05) (Figure 3.15A). 318 
 319 
ATP production was also significantly affected and reduced by an increase in the 320 
ratio of AA/DHA and decreased by 25% and 33% (P < 0.01) at 1:1 and 4:1, 321 
respectively. Furthermore, ATP production was reduced further at 15:1 and 25:1 322 
ratios (-44% and -41%, respectively, P < 0.001) (Figure 3.15B).  323 
 324 
The proton leak reduced significantly (P < 0.001) at only high AA/DHA ratios (15:1 325 
[41%] and 25:1 [50%]) as compared to the control; however, only the 25:1 ratio 326 
caused a significant decrease in proton leak (31%) (P < 0.01) as compared to the 327 
1:1 ratio (Figure 3.15C). Maximal respiration as well as spare respiratory capacity 328 
showed a gradual and remarkable reduction with an increase in the AA/DHA ratio. 329 
Thus, maximal respiration reduced gradually by 35% (P < 0.01), 44%, 54%, and 330 
56% (P < 0.001) (Figure 3.15D) for 1:1, 4:1, 15:1 and 25:1, respectively. A similar 331 
pattern occurred with the spare respiratory capacity which was significantly 332 
reduced by 52%, 56%, 67%, and 68% (P < 0.001) with increasing AA/DHA ratios 333 
compared to the control (Figure 3.15E).  334 
  335 
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 336 
 337 
Figure 3.14:  Effect of high AA/DHA ratio on the Seahorse Mito stress test 338 
parameters in VL-17A cells. A. Representative result. B. Model. AA, 339 
arachidonic acid; DHA docosahexaenoic acid. 340 
341 
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 342 
 343 
Figure 3.15: Effect increasing AA/DHA ratios on oxygen utilization in VL-344 
17A cells treated for 24 h. The results are presented as mean ± SEM (n = 4-5 345 
determinations, of 4 replicates per treatment). *P < 0.05, **P < 0.01, and ***P < 346 
0.001 as com-pared to the control; #P < 0.05 and ##P < 0.01 as compared to the 347 
value with the 1:1 ratio. AA, arachidonic acid. DHA, docosahexaenoic acid. 348 
 349 
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3.12. Effect of alcohol and arachidonic acid on cell viability and steatosis:  350 
Only a few studies have examined the interaction between alcohol and fatty acids 351 
(Gyamfi et al., 2012). It is possible additional factors such as alcohol increases 352 
the risk for disease development in NAFLD.  There is no data on this interaction 353 
with omega 6/3 ratios. VL-17A cells were treated separately with alcohol (100 354 
mM), AA (40 µM) and a mixture alcohol (100 mM plus AA 40 µM) for 6, 24, 48, 355 
and 72 h respectively, to investigate the effect on cell viability and lipid 356 
accumulation. Data showed that the cell viability remained unchanged after 6 h; 357 
however, it reduced significantly after 48 and 72 h with individual AA treatment (-358 
57% and -65%; P < 0.001, respectively) and alcohol/AA mixture (-63% and -64%; 359 
P < 0.001, respectively). In contrast, at 24 h, there was a slight non-significant 360 
decrease in the cell viability with alcohol/AA mixture (-14%, P = 0.06) (Figure 361 
3.16A-D). On the other hand, there was no increase in lipid accumulation at any 362 
time point. However, lipid accumulation decreased significantly at 48 and 72 h 363 
with individual AA (-18%; P < 0.001 and -54%; P < 0.01, respectively) and alcohol 364 
(-18% and -64%; P < 0.001, respectively) treatment as well as with the alcohol/AA 365 
mixture (-10%; P < 0.01 and -27%; P < 0.05, respectively) (Figure 3.16E-H). 366 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
 374 
 375 
 376 
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Figure 3.16: Effect of AA and/or alcohol on cell viability (A-D) & lipid 379 
accumulation (E-H) in VL-17A cells after 6, 24, 48, and 72 h. The results are 380 
presented as mean ± SEM (n = 3 determinations of 6 replicates per treatment). # 381 
P < 0.05, *P < 0.01, and **P < 0.001 as compared to the control. AA, arachidonic 382 
acid.   383 
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3.13 Effect of the AA/DHA and alcohol mixture on cell viability: 384 
VL-17A cells were exposed to different AA/DHA ratios (range 1:1–25:1) in the 385 
presence of (100 mM) alcohol for 24 h. Our data did not show any significant 386 
changes in the cell viability (P > 0.05). However, we found that cell viability 387 
significantly decreased at 15:1 (23%) and 25:1 (24%) ratios when compared to 388 
that at the alcohol/1:1 ratio only (P < 0.05) (Figure 3.17).  389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
Figure 3.17: Effect of increasing AA/DHA ratios in the presence of alcohol 401 
on cell viability in VL-17A cells after 24 h. The results are presented as mean 402 
± SEM (n = 3 determinations of 6 replicates per treatment). *P < 0.05 as 403 
compared to alcohol/1:1; **P < 0.05 as compared to alcohol/4:1. AA, arachidonic 404 
acid; DHA, docosahexaenoic acid. 405 
 406 
 407 
 408 
 409 
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3.14 Effect of (AA/DHA) ratio and alcohol mixture on ROS production: 410 
The production of ROS was measured after treating the VL-17A cells with four 411 
different ω-6/ω-3 (AA/DHA) ratios in the presence of alcohol (100 mM) for 30 min, 412 
1 h, and 2 h. There was no significant change with any ratio at the 30-min time 413 
point (Figure 3.18A). None of the ratios showed a significant difference as 414 
compared to the control after 1 h; however, only the 4:1 alcohol/omega ratio led 415 
to a significant, 39% (P < 0.05) reduction in ROS production. On the other hand, 416 
the 15:1 ratio caused an increase in the ROS levels; however, this elevation did 417 
not achieve statistical significance as compared to control (11%), but was 418 
significant when compared to that at the 4:1 ratio (Figure 3.18B).  419 
 420 
Only the higher alcohol/omega ratios (15:1 and 25:1), particularly the 25:1 ratio, 421 
stimulated ROS production after 2 h and caused a significant rise in the ROS 422 
levels. This elevation with the 15:1 and 25:1 ratios was observed mainly when 423 
compared to that in the control (49% and 73%; P < 0.01, respectively). However, 424 
when compared to the 1:1 and 4:1 ratios, the mixture of alcohol/15:1 ratio 425 
increased the ROS production (28%; P > 0.05 and 33%; P < 0.05, respectively); 426 
in addition, the ROS level elevation was significantly higher with the alcohol/ 25:1 427 
ratio (52% and 57%; P < 0.01, respectively) as compared to the 1:1 and 4:1 ratios 428 
(Figure 3.19). 429 
  430 
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Figure 3.18: Effect of increasing AA/DHA ratios in the presence of alcohol 460 
on ROS production in VL-17A cells after 30 min and 1 h treatment. The 461 
results are presented as mean ± SEM (n = 3 determinations of 6 replicates per 462 
treatment). *P < 0.05 as compared to the control; **P < 0.01 as compared to the 463 
value with 4:1 ratio in the presence of alcohol. AA, arachidonic acid. DHA, 464 
docosahexaenoic acid. 465 
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 476 
Figure 3.19: Effect of increasing AA/DHA ratios in the presence of alcohol 477 
on ROS production in VL-17A cells after 2 hr treatment. The results are 478 
presented as mean ± SEM (n = 3 determinations of 6 replicates per treatment). 479 
*P < 0.05 as compared to the value with 4:1 ratio in the presence of alcohol; **P 480 
< 0.01 as compared to the control; ***P < 0.01 as compared to the value with 4:1 481 
ratio in the presence of alcohol; #P < 0.01 as compared to the value with 1:1 ratio 482 
in the presence of alcohol. AA, arachidonic acid. DHA, docosahexaenoic acid. 483 
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3.15 Effect of chronic alcohol consumption on TNFα and liver function 485 
profile (LFT): 486 
There are many similarities between the pathological mechanisms between ALD 487 
and NAFLD, with hepatic inflammation are one of the prime manifestations. TNFα 488 
is a cytokine which is believed to be highly released in inflammation associated 489 
with ALD (DeSantis et al., 2013). Liver injury in ALD is normally accompanied by 490 
an increase in the markers of the liver function test and some cytokines (Zhang 491 
et al., 2017). To prove the above theory, the measurement of LFT and pro-492 
inflammatory cytokine (TNFα) in the serum of alcoholic patient was performed. 493 
Data showed a significant increase in the concentration of AST, ALT, ALP and 494 
GGT (Figure 3.21). In addition, serum TNFα concentration was also high but this 495 
increase did not achieve statistical significance as compared to control (P >0.05) 496 
(Figure 3.20). 497 
 498 
 499 
Figure 3.20: Box and Whisker plot of serum TNFα in ALD patients. TNFα, 500 
tumour necrosis factor; ALD, alcoholic liver disease. Data is Control n=15; 501 
ALD n=63.  502 
 503 
 504 
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 505 
Figure 3.21:  Effect of chronic alcohol consumption on liver injury markers in ALD 506 
patients. ALT, alanine aminotransferase; AST, aspartate; ALP, alkaline phosphatase; 507 
total bilirubin; GGT, gamma glutamyltransferase. Data is Control n=15; ALD n=63. *P 508 
<0.01, **P <0.001. 509 
 510 
 511 
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4. Discussion 524 
Non-alcoholic fatty liver disease (NAFLD) is one of the main types of chronic liver 525 
disease in obese children and adults (Rinella and Sanyal, 2016). Its 526 
characteristics include an excessive increase in hepatic triglyceride (TG) and 527 
cholesterol (simple steatosis). If not controlled, these can lead to steatohepatitis 528 
(Bae et al., 2017). As previously mentioned, hepatic steatosis is the prime 529 
manifestation of NAFLD. In addition, as stated earlier in chapter 1 (section 1.3.4), 530 
free fatty acids have a vital role in the development of NAFLD. Many studies 531 
discuss the relationship between high dietary consumption of omega-6 and a 532 
significant reduction in omega-3 consumption with the development of many 533 
diseases. These include cardiovascular disease, cancer (such as colorectal and 534 
breast cancer) and arthritis (Simopoulos, 2002; Candela et al., 2011). 535 
This study aimed to characterise the effect of various fatty acids (PA, SA, LA, 536 
ALA, DHA and AA) individually or as ratios (LA/ALA and AA/DHA) on lipotoxicity, 537 
liver steatosis, oxidative stress and mitochondrial function using HepG2 (VL-17A 538 
and VA-13) cells. A further aim was to demonstrate the particular implication of 539 
omega-6/3 ratios in the pathogenesis of NAFLD by investigating the effect on lipid 540 
metabolism as well as the cannabinoid system. In addition, this project examined 541 
the interaction of fatty acids and alcohol on cell toxicity and reactive oxygen 542 
species (ROS) production as well as alcohol alone on hepatic toxicity. 543 
 544 
4.1 Effect of saturated fatty acids 545 
To confirm that HepG2 cells could be used as a model for examining steatosis 546 
and lipotoxicity, fatty acids PA and SA were studied at various time points 547 
(Figures 3.1 and 3.2). Here the storage of TG by oil red staining indicated that PA 548 
  
87 
 
but not SA after 48 and 72 h showed a significant increase in lipid accumulation 549 
while both fatty acids caused cell toxicity. These results are consistent with a 550 
study that showed a toxic effect of PA and SA on SK-Hep-1 cells but at a higher 551 
concentration (250 µM and 500 µM, respectively) (Oh et al., 2012), than the 552 
present study (up to 160 µM). The results are also in relatively good agreement 553 
with other studies carried out by Zhang et al. (2011; 2012) where PA and SA (250 554 
µM) treatment significantly increased cell death of rat liver H4IIE cells and of 555 
primary rat hepatocytes, respectively. 556 
Gambino et al. (2016) found that the levels of PA and monounsaturated oleic acid 557 
were the highest circulating free fatty acids in patients with NAFLD. It is believed 558 
that the destabilisation of the lipid bilayer of the cellular membrane due to the 559 
unusual incorporation of saturated phospholipids. These form from excess 560 
unesterified saturated fatty acids and leads to endoplasmic reticulum (ER) stress 561 
(Spector and Yorek, 1985; Borradaile et al., 2006). Increased ER stress is 562 
associated with impairment of the unfolded protein response (UPR), which is 563 
required to restore ER homeostasis (Akazawa et al., 2010; Zhang et al., 2011; 564 
Zambo et al., 2013). Another study further supports this, showing that treatment 565 
of Wistar rats with a diet high in saturated fatty acids correlates highly with 566 
steatosis and ER stress (Wang et al., 2006). 567 
The significant elevation in lipid accumulation by PA can also arise via the 568 
activation of lipogenic enzymes. As mentioned previously (see section 1.3.2), the 569 
SCD1 enzyme is responsible for the conversion of PA and SA to 570 
monounsaturated fatty acids. Another factor is the activation of nuclear receptors 571 
such as the liver X receptor (LXR) and the pregnane X receptor (PXR). When 572 
both are highly expressed in the liver, this leads to the overexpression of SCD1 573 
and lipogenesis (Zhang et al., 2013). For example, treatment of neonatal cardiac 574 
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myocytes with PA and SA led to increased SCD1 expression, induced the 575 
accumulation of lipids and suppressed fatty acid oxidation (Matsui et al., 2012). 576 
 577 
4.2 Effect of omega-6 fatty acids 578 
Previous work from our laboratory (Gyamfi et al., 2012) demonstrated that PA at 579 
80 and 160 µM caused less damage to HepG2 cells than unsaturated fatty acids. 580 
PA had a mild damaging effect due to the low effect on ROS production and 581 
mitochondrial dysfunction. This suggests that unsaturated fatty acids may pose 582 
greater cell toxicity than saturated fatty acids. 583 
Omega-6 fatty acids LA and AA showed a cytotoxic effect on HepG2 cells, with 584 
AA expressing higher toxicity than LA (Figures 3.3 and 3.4) and greater than PA 585 
treatment by 72 h. After 24 h, LA (200–300 µM) showed a significant reduction in 586 
the viability of the cells. However, this decrease was only slightly significant after 587 
48 h and non-significant at 72 h compared to AA. This indicates the lower toxicity 588 
effect of LA on HepG2 cells. Muller et al. (2010) observed similar findings where 589 
a significant reduction in the viability of rat primary hepatocytes occurred after 48 590 
h of treatment with LA (100 µM), but in the presence of high glucose and insulin. 591 
An increase in oxidative stress as well as lipid accumulation resulted possibly due 592 
to the low cellular nitric oxide (NO) concentration. Many studies establish that NO 593 
acts as an antioxidant by binding to superoxide anion radicals and also limits fatty 594 
acid synthesis in the liver (Halliwell et al., 1999; Goldstein et al., 2000; Schild et 595 
al., 2006). Muller et al. (2010) found that LA reduced the concentration of cellular 596 
NO. It concomitantly increased both oxidative stress and the synthesis of fatty 597 
acids and consequently TG accumulation in hepatocytes.  In contrast, this study 598 
did not show a significant increase in lipid accumulation with LA, but there was a 599 
marked increase with AA especially after 48 h than with LA (Figures 3.3 and 3.4). 600 
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However, this rise with AA reduced significantly compared to control after 72 h, 601 
which suggests the high toxicity of AA or its immediate metabolites. 602 
A natural mechanism known as inflammation normally protects the human body 603 
from long-term injury. Inflammation produces physiological inflammatory 604 
mediators to defend the body. However, these mediators can be harmful and 605 
damage tissues if released inappropriately or in a higher proportion than normal 606 
levels (Maciejewska et al., 2015). As mentioned previously (see section 1.5), 607 
eicosanoids produced from polyunsaturated fatty acids LA and AA are among the 608 
main inflammatory mediators (Calder, 2010). Lipoxygenase (LOX) and 609 
cyclooxygenase (COX) can metabolise AA enzymatically to produce certain 610 
products. These include lipoxins (LX), leukotrienes (LT), hydroxyeicosatetraenoic 611 
acids (HETE), prostaglandins (PG) and hydroperoxyeicosatetraenoic acids 612 
(HPETE). Conversely, only LOX or non-enzymatic oxidative pathways can 613 
metabolise LA to produce the oxidative stress markers 9- and 13-614 
hydroxyoctadecadienoic acids (9-HODE and 13-HODE) (Maciejewska et al., 615 
2015). Therefore, the body metabolises AA and LA to a variety of inflammatory 616 
mediators considered causative components of steatohepatitis. 617 
However, several studies show AA produces stronger mediators than LA, which 618 
plays a key role in causing liver inflammation (Patterson et al., 2012; Kirack et al., 619 
2015; Maciejewska et al., 2015). For example, the levels of 9-HODE and 5-HETE 620 
mediators that LA and AA produced respectively were higher in patients with 621 
stage II NAFLD than in those with stage I. This could result from the higher activity 622 
of the 5-LOX enzyme (Maciejewska et al., 2015). In addition, LA eicosanoids (9-623 
HODE and 13-HODE) were elevated in patients with non-alcoholic 624 
steatohepatitis (NASH) compared to those with simple steatosis (Feldstein et al., 625 
2010). These studies confirm that the level of proinflammatory eicosanoids 626 
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produced from either AA or LA were high. Consequently, knowing the 627 
proinflammatory trait of AA and LA eicosanoids may explain the reduced viability 628 
of the cells in this study after the administration of AA and LA. Overall, these 629 
findings reflect the greater toxicity of AA compared with LA. In agreement with 630 
this work, a study that treated VA-13 cells for 24 h with AA showed a reduction in 631 
the level of cellular adenosine triphosphate (ATP) and mitochondrial membrane 632 
potential. This also showed an increase in ROS production as well as lipid 633 
accumulation, demonstrating the cytotoxic effects of AA (Gyamfi et al., 2012). 634 
It is interesting to note that cytochrome P450 (CYP) epoxygenases can also 635 
metabolise AA to epoxyeicosatrienoic acid (EET) eicosanoids. CYP is highly 636 
expressed in the liver and serves as a target for peroxisome proliferator-activated 637 
receptor alpha (PPAR-α) (Suzuki-Kemuriyama et al., 2016; Wells et al., 2016). 638 
EETs are potent and protective anti-inflammatory metabolites that soluble 639 
epoxide hydrolase (sEH), a broadly distributed cellular enzyme, can rapidly 640 
convert to a less active eicosanoid, dihydroxyeicosatrienoic acid (DHET) (Wells 641 
et al., 2016). The functional relevance of CYP epoxygenases in the pathogenesis 642 
of NAFLD remains unclear. However, some studies mentioned that the 643 
dysregulation of CYP epoxygenases and the suppression of the biosynthesis of 644 
circulating and hepatic EETs are a consequence of NASH (Schuck et al., 2014; 645 
Wells et al., 2016). 646 
On the other hand, ablation of one of the CYP 450 homologs, 4A14 (CYP4A14) 647 
which is involved in the hydroxylation of AA, correlates with attenuating hepatic 648 
fibrosis and inflammation in a CYP4A14-deficient mice model. This was also 649 
overexpressed in NAFLD patients and NAFLD murine models (Zhang et al., 650 
2017). Interestingly, Wells et al. (2016) found that the level of free anti-651 
inflammatory EET increased after the induction of NASH in mice and were also 652 
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high in patients with NASH. They also demonstrated that the genetic disruption 653 
of sEH enzyme in mice elevated the concentration of EETs and attenuated the 654 
previously induced steatosis and inflammation. It can be concluded from 655 
everything mentioned above that not all the elevated metabolites of AA lead to 656 
hepatic inflammation. However, some can be therapeutic and can attenuate the 657 
manifestations of NAFLD. 658 
 659 
4.3 Effect of omega-3 fatty acids 660 
Several studies have evaluated the efficacy of omega-3 in vivo and in vitro using 661 
omega-3 fatty acids as a treatment for proven NAFLD cases (Zhang et al., 2011; 662 
Bae et al., 2017; Hodson et al., 2017). However, one of the objectives of the 663 
current study was to know the effect of single fatty acids on VL-17A cells. 664 
Therefore, untreated cells were exposed to different omega-3 concentrations to 665 
indicate whether this class of fatty acids had the ability to reduce lipid content in 666 
untreated cells. It is common knowledge that omega-3 fatty acids (ALA and DHA) 667 
are more protective than omega-6 ones. Many studies report that omega-3 fatty 668 
acids (DHA and EPA) are low in patients with hepatic steatosis, which may 669 
suggest the efficacy of omega-3 in preventing and treating steatosis (Araya et al., 670 
2004; Allard et al., 2008; El-Badry et al., 2007; Patterson et al., 2012). The 671 
present study corroborated this where there was no observed cytotoxicity or 672 
change in lipid accumulation (Figures 3.5 and 3.6). 673 
Omega-3 derivatives (EPA and DHA) seem to act as activators of PPARα. 674 
PPARα has a role in promoting lipid oxidation, which can be associated to the 675 
protective effect of the omega-3 family. In one study, ALA reversed the effect SA 676 
elicited and reduced apoptosis as well as ER stress in rat hepatocytes (Zhang et 677 
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al., 2011). This protective effect of ALA may be due to the conversion of ALA to 678 
its derivatives (EPA and DHA). It may also result from modulating some metabolic 679 
processes directly through the activation of some receptors such as PPARα or 680 
regulating inflammatory mediator pathways (Hanke et al., 2013). 681 
Another possible mechanism is the expression of SCD1, which converts 682 
saturated fatty acids to unsaturated fatty acids. Caputo et al. (2014) found that 683 
DHA reduced the activation of liver X receptor alpha (LXRα). Consequently, this 684 
decreased the activity of SREBP-1c and the binding of this transcriptional factor 685 
(SREBP1-c) to SCD1. In turn, this led to reduced TG synthesis and accumulation 686 
of lipids in hepatocytes. Furthermore, Kheder et al. (2016) agreed with other 687 
studies and showed that vitamin D3 and DHA either separately or as a mixture 688 
were able to down- and upregulate the activity of SREBP and PPARα, 689 
respectively. In addition, they reduced the production of tumor necrosis factor 690 
alpha (TNFα, a proinflammatory cytokine from macrophages), which can induce 691 
hepatic stellate cells to develop fibrosis. This is consistent with a study conducted 692 
on children with NAFLD and vitamin D deficiency. Here again, administering both 693 
DHA and vitamin D improved insulin resistance and reduced the activation of 694 
stellate cells and consequently collagen content (Della Corte et al., 2016). 695 
From the data presented and documented above, it is likely that this protective 696 
impact of omega-3 fatty acids can be due to their effect on the activity of SREBP 697 
and PPARα. As stated these helps metabolise fatty acids by modulating the 698 
accumulation of lipids in the hepatocytes. This can take place through the 699 
inhibition of fat biosynthesis and consequently suppress the development of 700 
steatosis (Suzuki-Kemuriyama et al., 2016). 701 
Several studies have reported that EPA and DHA have the ability to improve the 702 
pathological features of NASH. Moreover, EPA is more functional than DHA in 703 
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reducing hepatic steatosis by decreasing the expression of lipogenic genes 704 
involved in fatty acid and TG synthesis. These include fatty acid synthase (FAS), 705 
glycerol-3-phosphate acyltransferase (GPAT1, an enzyme involved in TG 706 
synthesis), and elongation of very long-chain fatty acids (Elovl6). The latter is a 707 
microsomal enzyme that plays a role in the elongation of saturated and 708 
monousaturated fatty acids, mainly C16 to C18, and serves as a target enzyme 709 
for SREBP in the liver. In contrast, these studies found DHA more efficient in 710 
attenuating the level of ROS, fibrosis and hepatic inflammation (Matsuzaka et al., 711 
2012; Depner et al., 2013; Suzuki-Kemuriyama et al., 2016). 712 
The expression of nicotinamide adenine dinucleotide phosphate (NADPH) 713 
oxidase subunits can also serve as a marker for oxidative stress. The belief is 714 
that this enzyme has a key role in the pathogenesis of NASH, especially in fibrosis 715 
(De Minicis and Brenner, 2007). NADPH oxidase can generate a superoxide via 716 
transferring an electron from NADPH along the cellular membrane to bind to 717 
molecular oxygen and form a superoxide anion. In turn, superoxide dismutase 718 
can convert the anion to hydrogen peroxide. However, DHA has more potential 719 
than EPA in attenuating the expression of the NADPH oxidase subunits involved 720 
in oxidative stress (Depner et al., 2013). 721 
In conclusion, all the mechanisms mentioned above can help in understanding 722 
how omega-3 fatty acids can be protective and attenuate the pathological 723 
manifestations of NAFLD. This in turn can clarify in this study, why both ALA and 724 
DHA did not cause any lipotoxicity or lipid accumulation when they were used as 725 
a treatment. 726 
 727 
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4.4 Effect of increased omega 6/3 ratio on cellular toxicity and steatosis 728 
In this study, it was hypothesised that high omega 6/3 ratios will cause high cell 729 
toxicity and lipid accumulation. Here, LA/ALA and AA/DHA findings were not 730 
entirely consistent with other research. These studies showed a link between an 731 
increased ω6/ω3 ratio and the development of hepatic steatosis (Araya et al., 732 
2004; Puri et al., 2007). Thus, treatment with LA/ALA ratios did not affect the 733 
viability of cells (Figure 3.7A-C) nor cause an increase in the accumulation of 734 
lipids (Figure 3.7D-F) This could be due to the low concentration of LA used in 735 
this study. In contrast, AA/DHA ratio findings showed a significant decrease in 736 
cell viability after 24, 48 and 72 h when the ratios increased (Figure 3.8A-C). 737 
Unexpectedly, the oil red method data did not show a significant increase in lipid 738 
accumulation, and at 72 h, some ratios showing a significant decrease (Figure 739 
3.8D-F).  740 
Enzymatic quantification of the concentration of intracellular TG helped confirm 741 
the data above. This method expresses the lipid content in relation to cell protein 742 
content. In contrast to the previous data the oil red method provided, results 743 
indicated a significant elevation in lipid concentration, especially after 24 h and 744 
48 h (Figure 3.9A-B). These results agree with other studies where the omega 745 
6/3 ratio was high in the livers of patients with NAFLD exhibiting steatosis and 746 
NASH (Araya et al., 2004; Puri et al, 2007). These findings are also similar to a 747 
study by Enos et al. (2015) in which they fed male mice a high-fat diet with 748 
different omega AA/EPA and AA/DHA ratios (1:1, 5:1, 10:1 and 20:1). This 749 
caused hepatomegaly with a significant increase in hepatic lipid accumulation. 750 
Nutritional factors along with increased oxidative stress and factors like the 751 
development of insulin resistance play a crucial role in changing hepatic 752 
metabolism and developing steatosis (Farrell and Larter, 2006; Musso et al., 753 
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2009; Gormaz et al., 2010). Therefore, overload of FA in the liver correlates with 754 
the rise in the mitochondrial oxidation of FA. Consequently, increased hepatic 755 
oxidative stress leads to the progression of steatohepatitis (Valenzuela and 756 
Videla, 2011). This theory is consistent with this study in which high AA/DHA 757 
ratios increased the intracellular amount of lipids. However, a discussion and 758 
evaluation of oxidative stress in this study and the production of ROS will occur 759 
later in this chapter. 760 
The dysregulation of lipid metabolism in the liver can be another factor in the 761 
development of steatosis. In this research, the increase in the concentration of 762 
TG with high AA/DHA ratios can be also due to low DHA and high AA 763 
concentrations. Depletion of omega-3 seems to increase the lipogenic capacity 764 
by favouring TG and FA synthesis. This causes derangement in the oxidation of 765 
FA and decreases the export of TG from the liver. Subsequently, this 766 
downregulates PPARα and activates SREBP, which in turn promotes the 767 
development of steatosis and inflammation (Valenzuela and Videla, 2011). 768 
As mentioned previously, the significant decrease in cell viability can be due to 769 
the increase of AA metabolites, which are considered as strong mediators of liver 770 
inflammation. Conversely, EPA and DHA can antagonise the effect of these 771 
mediators. Furthermore, in a study by Suzuki-Kemuriyama et al. (2016), EPA and 772 
DHA were able to suppress the synthesis and metabolism of ω6 fatty acids and 773 
reduce the content of AA. This in turn can clarify the reason behind the low 774 
viability of the cells in this study with high omega 6/3 ratios and consequently the 775 
development of steatosis. 776 
Therefore, further work must take place to evaluate the effect of high omega 6/3 777 
ratios on the expression of omega 6 inflammatory products. This may then 778 
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provide valuable information into how high omega 6/3 ratios can induce liver 779 
inflammation, which is the prime manifestation of NASH. 780 
 781 
4.5 Effect of high AA/DHA ratios on hepatic lipid metabolism 782 
This study aimed to investigate the mechanism behind the elevated amount of 783 
lipid in liver cells. To this end, the protein expression of SREBP-1c, SCD1 and 784 
PPARα and cannabinoid receptors (CB1 and CB2) involved in hepatic lipid 785 
metabolism was determined. The present study presumed that high AA/DHA 786 
ratios will lead to changes in the expression of these transcriptional factors. 787 
Unpredictably, treating VL-17A cells with different AA/DHA ratios for 24 h did not 788 
cause an expected increase in the expression of SREBP-1c, a lipogenic factor 789 
known to promote the synthesis of lipids. Thus, these findings contrast with those 790 
in other studies. For example, Zhang et al. (2014) found that the expression of 791 
SREBP-1c was upregulated in HepG2 cells after treating the cells with a LXR 792 
agonist. This was the TO901317 drug, known for activating the SREBP-1c 793 
promoter. In addition, this upregulation led to an increase in the expression of 794 
SCD1 after infecting HepG2 cells with an adenovirus expressing SREBP-1c. 795 
Also, mice fed a high-fat diet with different ratios of omega 6/3 led to increased 796 
SREBP-1c expression (Enos et al., 2015). 797 
Moreover, supplementation of omega-3 fatty acid in ob/ob mice downregulated 798 
the expression of SREBP-1 and consequently liver lipogenesis. It also reduced 799 
the levels of serum fatty acids, insulin and glucose (Sekiya et al., 2003). This 800 
study illustrated that a low omega-3 fatty acid level usually upregulates the 801 
expression of SREBP-1. This is similar to the current study where omega-3 fatty 802 
acids were not in balance with omega-6 ones. Further support for this notion 803 
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comes from feeding mice a diet lacking omega-3 fatty acids. This activates 804 
SREBP-1c and lipogenesis as compared with control mice (Pachikian et al., 805 
2011). However, this project’s findings agree with a study conducted on a 806 
Chinese population with NAFLD. This study assessed the impact of four single-807 
nucleotide polymorphisms (SNPs) in SREBP-1c on NAFLD vulnerability. They 808 
also found that these four SNPs in SREBP-1c did not correlate with the risk of 809 
NAFLD in the Chinese Han population (Peng et al., 2016). Furthermore, the 810 
results demonstrated that SNP alleles in SREBP-1c vary between different 811 
populations with various genetic backgrounds. It is also important to state that 812 
NAFLD is a multifactorial disease that develops due to different environmental 813 
factors and genetic changes. 814 
However, the current findings relate to work by Shimomura et al. (1997) where 815 
HepG2 cells, diploid human fibroblasts and mouse embryo fibroblasts produce 816 
more SREBP-1a than SREBP-1c. Conversely, the SREBP-1c isoform is more 817 
predominant in human liver and adipose tissue than in cultured cells. After 818 
incubating HepG2 cells with either a medium supplemented or lacking sterol, 819 
RNA was isolated and both treated cells showed higher SREBP-1a transcripts 820 
than SREBP-1c. This variance was even higher in the sterol-deficient medium 821 
(Shimomura et al., 1997). This may explain the lack of expression change in 822 
SREBP-1c in the present study. 823 
 824 
Although these findings showed no change in the expression of SREBP-1c 825 
especially with high ratios, SCD1 expression, a lipogenic enzyme, was up-826 
regulated at 15:1 and this effect was even more pronounced at 25:1 ratio (Figure 827 
3.11F). As mentioned previously in chapter 1 (see section 1.3), polyunsaturated 828 
fatty acids constitute a factor involved in the regulation of SCD1 expression. This 829 
  
98 
 
can occur either directly by binding to LXR or indirectly through the activation of 830 
SREBP-1c via LXR. LXR is a member of the nuclear hormone receptor family 831 
and is highly abundant in the liver and other organs such as the kidney and 832 
spleen. Furthermore, it has the ability to regulate cholesterol and fatty acid 833 
homeostasis and can be activated by sterol and FFAs (DeBose-Boyd et al., 2001; 834 
Chuu et al., 2007; Zhang et al., 2014). Therefore, this study can attribute the high 835 
expression of the SCD1 enzyme to its binding to LXR and not to the activation of 836 
SREBP-1c since the expression of the latter did not indicate any change. These 837 
findings are consistent with those in which SREBP-1c null mice treated with the 838 
LXR agonist TO901317 showed a slight increase in SCD1 expression (Zhang et 839 
al., 2014). Researchers in another study fed mice a diet enriched in saturated 840 
and omega-6 fatty acids and low in omega-3. Results showed a high liver 841 
expression of SREBP-1 and SCD1 while PPARα showed limited expression 842 
(Sealls et al., 2008). Yet these findings partly disagree with what Caputo et al. 843 
(2014) reported. That study showed polyunsaturated fatty acids (AA, DHA and 844 
EPA) can inhibit LXRα activation. Consequently, they can inhibit the activation of 845 
SREBP-1 and SCD1. However, the current study can accept Caputo et al.’s 846 
(2014) findings in terms of DHA but not for AA. 847 
The elevation of the omega 6/3 ratio in the present study increased the 848 
expression of SCD1. Consequently, this agrees with what Miyazaki et al. (2007) 849 
found, where SCD1-deficient mice fed a high fat-diet protected these animals 850 
from the onset of hepatic steatosis. This reflects the role of SCD1 in the 851 
development of steatosis. Thus, further work is needed to identify the role of a 852 
high omega 6/3 ratio in regulating the activity of LXR. 853 
Most studies evaluate the expression of SREBP along with PPARα in studying 854 
the lipogenic pathways. Thus, to study the impact of high AA/DHA ratios on lipid 855 
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metabolism, the effect of these ratios on the expression of PPARα was evaluated. 856 
This transcriptional factor stimulates FA oxidation by activating enzymes such as 857 
acyl-CoA oxidase (ACO) in the peroxisome and carnitine palmitoyltransferase I 858 
(CPT1) in the mitochondria (El-Badry et al., 2007). As hypothesised in this study, 859 
high ratios of AA/DHA (15:1 and 25:1) significantly downregulated the expression 860 
of PPAR-α (Figure 3.10B). The supplementation of omega-3 fatty acids (EPA and 861 
DHA) in mice fed a high-fat diet led to upregulated expression of PPARα. 862 
Consequently, this prevented hepatic steatosis and inflammation (Tapia et al., 863 
2014). This theory can explain the low expression of PPARα in this study where 864 
omega-3 fatty acids were not in balance and were lower than omega-6. 865 
Overall, these findings showed that high AA/DHA ratios affected both fatty acid 866 
oxidation and lipogenesis by decreasing PPARα expression and upregulating 867 
SCD1 expression, respectively.  The latter, possibly activated in this study by 868 
LXR and not SREBP1-c because the expression of SREBP1c did not change. 869 
This calls for further investigations on the effect of AA/DHA ratios on LXR activity 870 
or to study the impact of these ratios on the expression of SREBP1-c using animal 871 
liver instead. However, these findings are consistent with data from TG assays in 872 
which lipid levels increased by increasing the AA/DHA ratio. 873 
 874 
4.6 Effect of high AA/DHA ratios on the cannabinoids system 875 
As mentioned in chapter 1 (section 1.3.5), high fatty acids can increase the level 876 
of endocannabinoids and consequently activate the expression of CB1 and CB2. 877 
To some extent, this is consistent with this study’s findings where CB1 expression 878 
increased slightly with high AA/DHA ratios. However, this elevation was not 879 
significant, which is possibly due to the short incubation time. As described 880 
earlier, the expression of SCD1 and not SREBP-1c increased while PPARα 881 
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decreased. This may be the reason behind the slight increase in CB1 receptor 882 
expression with high AA/DHA ratios.  883 
Osei-Hyiaman et al. (2005) found that after feeding CB1-deficient mice and wild-884 
type mice a high-fat diet for 14 weeks, only the latter developed steatosis. 885 
Moreover, the results showed an elevated CB1 expression in the wild-type group 886 
while the level of the endogenous cannabinoid anandamide, which activates CB1 887 
receptors, increased in both groups. Furthermore, activating CB1 receptors via a 888 
CB1 agonist in wild-type mice fed a chow diet increased the expression of 889 
SREPB1-c and lipogenic enzymes (involved in fatty acid synthesis). It can be 890 
concluded from their study that a high-fat diet activates CB1 receptors via 891 
increasing the level of anandamide. This consequently leads to fatty liver 892 
development by upregulating the expression of SREBP-1c and lipogenic 893 
enzymes. 894 
In another study, the researchers also investigated the impact of a high-fat diet 895 
on metabolic pathways using wild-type mice and liver CB1-deficient mice (Osei-896 
Hyiaman et al., 2008). Here, both mice species developed obesity but the liver 897 
CB1-deficient mice developed less hyperglycaemia, insulin resistance, 898 
dyslipidaemia and steatosis than the wild-type mice. This suggests that the 899 
activation of endocannabinoids induces the expression of CB1 receptors causing 900 
some metabolic and hormonal alterations and consequently contributes in the 901 
development of steatosis. 902 
Unlike the moderate number of studies conducted on CB1 receptors and their 903 
role in the development of fatty liver, the expression and the role of CB2 receptors 904 
in the development of NAFLD is still unclear and under-investigated. Compared 905 
with the control and in contrast to the current findings, high AA/DHA ratios did not 906 
result in increased expression of CB2. Instead, the opposite occurred, with all 907 
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ratios (1:1–25:1) showing a significant reduction in CB2 expression, particularly 908 
with 1:1 and 4:1 ratios. However, comparing all ratios to 1:1 showed an increase 909 
in CB2 expression, which was significant at the 25:1 ratio. Thus, our study agrees 910 
with Mendez-Sanchez et al. (2007), who showed upregulation of the expression 911 
of CB2 receptors in the livers of NAFLD patients characterised by steatosis and 912 
steatohepatitis. Moreover, feeding mice a high-fat diet for 15 weeks caused fatty 913 
liver and increased TG levels. Conversely, CB2 knockout mice fed the same diet 914 
showed less hepatic steatosis (Deveaux et al., 2009). Julien et al. (2005) also 915 
demonstrated that CB2 receptors are not expressed in normal livers but only in 916 
cirrhotic livers and are upregulated in hepatic fibrogenic cells. The researchers 917 
surmised that activated CB2 receptors act as anti-fibrogenic factors by triggering 918 
apoptosis and growth inhibition like cyclooxygenase-2. 919 
Altogether, these data indicate that CB2 receptors are mainly expressed in liver 920 
fibrogenic cells and cirrhotic livers but not in normal livers to counteract fibrosis. 921 
This can be the reason behind the low expression of CB2 in the present study. 922 
This can also be due to the short exposure of the cells to the treatments, 923 
assuming they may require longer time to induce severe injury with high AA/DHA 924 
ratios and consequently increase CB2 expression. This notion can be consistent 925 
with the present study’s findings that the expression of CB2 receptors was 926 
significantly low at 1:1 and 4:1 ratios. Conversely, 15:1 and particularly 25:1 ratios 927 
expressed more CB2 receptors than the 1:1 ratio. 928 
To our knowledge, this study has demonstrated for the first time that cannabinoid 929 
receptors correlate to high omega 6/3 ratios. However, further work can elucidate 930 
the effect of high AA/DHA ratios on the expression of CB2 receptors by evaluating 931 
inflammatory markers like TNFα and fibrogenic ones. Additional studies could 932 
also help identify the mechanism by which high AA/DHA ratios affect and 933 
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upregulate the expression of CB1. It would thus be useful to investigate the 934 
expression of other enzymes involved in either fatty acid oxidation like CPT1 or 935 
in lipogenesis such as FAS. 936 
  937 
4.7 Effect of increased AA/DHA ratios on mitochondrial functions and ROS 938 
production 939 
Research has established that free fatty acids correlate with mitochondrial 940 
dysfunction via the uncoupling of oxidative phosphorylation (Schonfeld and 941 
Wojtczak, 2008). The current study followed the concept above and the previous 942 
investigation on the effect of high AA/DHA ratios on lipid metabolism. To this end, 943 
the influence of polyunsaturated free fatty acids as a ratio (AA/DHA) on 944 
mitochondrial dysfunction was assessed by measuring the cellular oxygen 945 
consumption rate. Here, high AA/DHA ratios (15:1 and 25:1) led to mitochondrial 946 
function disturbance along with a significant decrease in mitochondrial respiration 947 
and the production of ATP (Figure 3.14). This impairment of mitochondrial 948 
oxidative respiration was accompanied by a reduction in the proton leak as well 949 
as the ability of the cells to achieve their maximal respiration and to respond to 950 
elevated energy demand. 951 
The mechanism behind this mitochondrial dysfunction and ATP synthesis 952 
depletion could be due to the destabilisation of cytochrome c in the electron 953 
transport chain (ETC) by fatty acids. This in turn decreases the flow of electrons 954 
in the respiratory chain and beyond complex II, inducing the release of electrons 955 
from the mitochondrial membranes (Schonfeld and Wojtczak, 2008). 956 
Mitochondrial dysfunction due to the accumulation of fatty acids can also result 957 
from (as stated in Chapter 1 section 1.3.4) electron leakage. Also, can be due to 958 
the ability of fatty acids to increase the permeability of the mitochondrial 959 
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membrane by stimulating the opening of the mitochondrial permeability transition 960 
(MPT) pores in the inner mitochondrial membrane. This leads to mitochondrial 961 
depolarisation, loss of membrane potential by uncoupling and consequently 962 
swelling, leading to cell death (Jaeschke et al., 2002). 963 
Proton leak is one of the parameters of mitochondrial function that reflects any 964 
damage to the mitochondria. In addition, the reduction of proton leak in this study 965 
can be attributed to the reduced electron flow in the ETC. This usually 966 
accomplished by proton pump from the mitochondrial matrix into the 967 
mitochondrial intermembrane space. Proton pump reduction will then lower 968 
protons entering through the channel of complex V and consequently decreases 969 
the production of ATP. 970 
Overall, these data agree with the work by Gyamfi et al. (2012). This study found 971 
that AA reduced the mitochondrial membrane potential and ATP production more 972 
than PA in VA-13 cells. The present study used AA as the main source of omega-973 
6 fatty acids. Several studies have reported altered mitochondrial function in fatty 974 
liver disease. Oliveira et al. (2006) showed disruption of mitochondrial function 975 
occurred in Wistar rats with fatty liver. Their study found mitochondrial dysfunction 976 
represented by a reduction in respiratory control rate, an increase in the oxygen 977 
consumption rate and an increase in oxidative stress. Petrosillo et al. (2007) 978 
showed similar results with reduced complex I activity in the livers of rats with 979 
fatty liver. This also correlated with an increase in the production of hydrogen 980 
peroxide (H2O2), which could explain the significant decrease in the complex I 981 
activity. Another study reported mitochondrial uncoupling in obese individuals 982 
with NASH and a respiration rate decreased by 30–40% (Koliaki et al., 2015). 983 
Following the evaluation of mitochondrial function, this study assessed the effect 984 
of AA/DHA ratios on ROS production. As stated in chapter 1 (section 1.3.4), ROS 985 
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mainly produced from the mitochondria, and complex I and III are the main sites 986 
of electron leakage leading to ROS production (Schonfeld and Wojtczak, 2008). 987 
The increase in ROS production normally arises as a response to mitochondrial 988 
dysfunction (Leamy et al., 2013). This theory is consistent with the findings of this 989 
study, where high AA/DHA ratios caused mitochondrial dysfunction. The study 990 
also found that all the AA/DHA ratios increased the production of ROS after 30 991 
min. But over time, this elevation at 1:1 and 4:1 went down to normal levels while 992 
with high ratios, ROS remained elevated, especially at the 15:1 ratio. This 993 
reduction in ROS at 1:1 and 4:1 could be due to the oxidation of fatty acids, 994 
coupled with the respiratory chain handling the excess release of electrons. This 995 
also facilitates the movement of electrons through the respiratory chain to reduce 996 
oxygen atoms into water instead of producing ROS. 997 
The elevation in ROS levels with high AA/DHA ratios can be attributed to the 998 
inhibition of complex I and III via these ratios where the concentration of AA was 999 
higher and imbalanced with DHA. As it is known that (AA) acts as a strong 1000 
inhibitor of complexes I and III of the respiratory chain (Cocco et al., 1999; 1001 
Dymkowska et al 2006). In addition, the inhibition of these complexes prevents 1002 
the flow of electrons through the respiratory chain. Consequently, electron leak 1003 
from complex I and III will reduce the mitochondrial membrane potential and 1004 
promote ROS production. This in turn increases oxidative stress and damages 1005 
cell membranes by inducing the production of certain lipid diffusible molecules 1006 
like malondialdehyde and 4-hydroxynonenal. These findings are in agreement 1007 
with Gyamfi et al. (2012) where the production of ROS increased in VA-13 cells 1008 
with AA. The researchers suggested that electron leakage from complex I caused 1009 
this elevation in ROS production. Furthermore, Dymkowska et al. (2006) reported 1010 
that AA, PA and oleic acid induced ROS production in rat liver AS-30D cells. They 1011 
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demonstrated this can be as a result of the inhibition of complex I and III in the 1012 
ETC via these fatty acids. 1013 
When inducing steatosis in HepG2 cells using high concentrations of PA and oleic 1014 
acid, these conditions led to an increase in ROS production and a decline in ATP 1015 
production (Zhang et al., 2011). Interestingly, when treating these steatotic cells 1016 
with high concentrations of DHA or EPA omega-3 fatty acids, ROS production 1017 
decreased and ATP production increased. On the other hand, in this study, DHA 1018 
concentration was low and imbalanced with AA at high omega ratios. This in turn 1019 
can explain the ROS increase and the reduction in ATP production. In addition, 1020 
lipid accumulation normally accompanies an increase in the beta-oxidation of 1021 
fatty acids. This in turn increases the production of acetyl coenzyme A (acetyl-1022 
coA) and its metabolism in the tricarboxylic acid (TCA) cycle. Consequently, this 1023 
also increases the delivery of substrates like reduced nicotinamide adenine 1024 
dinucleotide (NADH) to the ETC. The increase of these substrates stimulates the 1025 
production of ROS. This can then be one of the mechanisms leading to an 1026 
upsurge in ROS in this study with high AA/DHA ratios (Gusdon et al., 2014). 1027 
Studies have shown that the CYP2E1 enzyme seems to be involved in the 1028 
pathogenesis of NAFLD. The enzyme has a role in the hydroxylation of omega 1029 
fatty acids, and a high-fat diet can also induce it (Daly, 2013; Abdelmegeed et al., 1030 
2015). Research has also revealed that the CYP2E1 isoform is not only 1031 
expressed in the ER but also in the mitochondria. Moreover, CYP2E1 is 1032 
overexpressed in rat hepatocytes and patients with steatohepatitis (Weltman, et 1033 
al. 1996; 1998; Abdelmegeed et al., 2015). This can be a possible cause of the 1034 
increase in ROS production in this study with high AA/DHA ratios. The induction 1035 
of CYP2E1 via a high-fat diet or alcohol increases the level of ROS and reactive 1036 
nitrogen species like nitric oxide (NO). This in turn causes mitochondrial damage 1037 
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by stimulating the peroxidation of the mitochondrial lipid membrane. Furthermore, 1038 
it damages mitochondrial DNA and consequently components of the ETC. 1039 
Ultimately, this causes mitochondrial dysfunction (Aubert et al., 2011; 1040 
Abdelmegeed et al., 2015). However, other studies did not agree with this notion 1041 
and report that there is no evidence of the contribution of CYP2E1 in the 1042 
pathogenies of NAFLD. Thus, whether this enzyme intervenes in NAFLD 1043 
pathogenesis for certain is still unclear (Daly, 2013). 1044 
Altogether, AA/DHA ratios caused mitochondrial dysfunction and reduced the 1045 
production of ATP, which an increase in the production of ROS also 1046 
accomplished. These findings suggest that high AA/DHA ratios caused a 1047 
disturbance in the ETC by increasing the permeability of the inner mitochondrial 1048 
membrane and the production of ROS. Consequently, this caused mitochondrial 1049 
uncoupling and ended up causing mitochondrial dysfunction. 1050 
 1051 
4.8 Effect of AA/DHA ratios in the presence of alcohol on cell viability and ROS 1052 
production 1053 
To recap, this study assessed the effect of AA/DHA ratios on lipid metabolism, 1054 
mitochondrial function and ROS production. The misuse of alcohol also plays a 1055 
role in the development of fatty liver. Thus, it was also interesting to determine 1056 
the impact of these ratios in the presence of alcohol on cell viability and ROS 1057 
production. However, prior to the performance of these investigations, this study 1058 
sought to understand the effect of alcohol when mixed with AA. Thus, the impact 1059 
of an AA (40 µM) and alcohol (100 mM) mixture alone on cytotoxicity and lipid 1060 
accumulation was evaluated. Findings showed that an AA/alcohol ratio during the 1061 
first 6–24 h did not affect the viability of the cells nor lipid accumulation. However, 1062 
after 48 and 72 h, there was a pronounced decrease in the viability of the cells 1063 
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accompanying a slight reduction in lipid accumulation (Figure 3.16). These 1064 
findings had a similar pattern of change when exposing the cells to AA alone, 1065 
because treating the cells with alcohol only did not show any change in both 1066 
parameters (Figure. 3.16). 1067 
This contrasts with Huang, et al. (2013), where they induced steatosis in mice 1068 
with acute alcohol administration. This suggests the reduction in cell viability is 1069 
most probably due to the effect of AA and not alcohol. As mentioned above, 1070 
alcohol was not able to induce any cell toxicity or lipid accumulation. This may 1071 
result from the fact that VL-17A cells overexpress CYP2E1 and alcohol 1072 
dehydrogenase (ADH) enzymes. Both play roles in alcohol oxidation, and this 1073 
may explain the rapid oxidation of alcohol. However, the proinflammatory effect 1074 
of AA eicosanoids may affect this study’s findings as stated in this chapter 1075 
(section 4.2). These findings to some extent are consistent with Gyamfi et al. 1076 
(2012). This study found both alcohol and AA alone caused a loss in 1077 
mitochondrial membrane potential with a reduction in ATP production and an 1078 
increase in lipid accumulation. Treating VA-13 cells with AA in the presence of 1079 
alcohol (100 mM) further enhanced this effect. However, the difference in results 1080 
could be because VA-13 cells overexpress the ADH enzyme only. 1081 
A study that Vatsalya et al. (2016) conducted on an alcoholic patients confirmed 1082 
liver injury via high alanine transaminase (ALT) and aspartate transaminase 1083 
(AST) levels. At the same time, they also measured the fatty acid profile, which 1084 
showed an increase in the omega 6/3 ratio. This study sought to evaluate the 1085 
effect of AA/DHA ratios in the presence of alcohol on cell viability. Thus, VL-17A 1086 
cells were treated with alcohol and different AA/DHA ratios ranging from 1:1 to 1087 
25:1 for 24 h. No change in cell viability occurred when compared to controls. 1088 
However, high AA/DHA ratios in the presence of alcohol caused a marked 1089 
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reduction in cell viability when compared to 1:1 and 4:1 ratios in the presence of 1090 
alcohol (Figure 3.17). On the other hand, greater lipotoxicity resulted after 1091 
exposing VL-17A cells to the same AA/DHA ratios without alcohol. 1092 
Nevertheless, after investigating the effect of the same treatments on ROS 1093 
production, it did not occur in the first 30 min to 1 h. Yet after 2 h, 15:1 and 25:1 1094 
ratios showed a significant increase in ROS (Figures 3.18 and 3.19). The 1095 
excessive and prolonged consumption of alcohol is highly correlated with the 1096 
onset of alcoholic liver disease (ALD). Chapter 1 (section 1.7) outlined some 1097 
mechanisms in which alcohol can increase the level of ROS. Briefly, chronic 1098 
alcohol consumption and high alcohol concentrations can induce the CYP2E1 1099 
enzyme in the endoplasmic reticulum to oxidise alcohol to acetaldehyde. ROS 1100 
production accompanies this step, causing endoplasmic reticulum (ER) stress. 1101 
In addition, the cytosol mainly oxidises alcohol via the ADH enzyme into 1102 
acetaldehyde. In turn, nicotinamide adenine dinucleotide (NAD) reduction to 1103 
NADH accompanies this. Aldehyde dehydrogenase (ALDH2) then further 1104 
oxidises acetaldehyde into acetate in the mitochondria with NAD reduction to 1105 
NADH again. NADH will then be oxidised in the ETC, and the excessive 1106 
production of NADH leads to an increase in the NADH:NAD ratio. This plays a 1107 
role in the MPT, which in turn causes mitochondrial swelling leading to 1108 
mitochondrial dysfunction. An elevated NADH:NAD ratio in the mitochondria also 1109 
leads to ETC disturbance and increases electron leakage in complex I and III. 1110 
Consequently, this increases ROS production, which in turn elevates the level of 1111 
oxidative stress in the mitochondria (Akie et al., 2015). 1112 
In summary, whether this rise in ROS levels results from the effect of either 1113 
AA/DHA or alcohol or as a result of both is still unclear. However, earlier this 1114 
chapter (section 4.7) outlined the reason behind the increase in ROS production 1115 
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via AA/DHA ratios. This study suggests that this effect is due to mitochondrial 1116 
dysfunction. The increase in ROS levels may also result from the effect of alcohol 1117 
via the influence of its metabolites in the ETC. Subsequently, this leads to 1118 
mitochondrial dysfunction. Despite the effect of alcohol (100 mM), evaluating 1119 
ROS production did not show any change at any time. Alcohol findings are not 1120 
consistent with Bailey et al. (1999) and Stiuso et al (2016). In these studies, 1121 
ethanol increased ROS production and reduced cell viability in rat hepatocytes 1122 
and HepG2 cells. These data indicate that the increase in ROS levels in this study 1123 
may result from high AA:DHA ratios and not due to the effect of alcohol. This may 1124 
be because CYP2E1 and ADH enzymes in VL-17A cells rapidly metabolised the 1125 
alcohol. In addition, the increase in ROS levels may be due to the activation of 1126 
CYP2E1 via the high AA:DHA ratios as indicated in this chapter (4.7). A high-fat 1127 
diet can be one factor inducing CYP2E1. Therefore, further work using different 1128 
cell types, like VA-13, may elucidate the influence of AA:DHA ratios in the 1129 
presence of alcohol in ALD development. Finally, no studies use differing ratios 1130 
of omega 6/3 in the presence of alcohol studying mitochondrial function. 1131 
 1132 
4.9 Chronic alcohol consumption and pro-inflammatory cytokines 1133 
ALD has a broad spectrum of liver injury ranging from liver steatosis to 1134 
steatohepatitis. Inflammation characterises the latter, which can then develop to 1135 
fibrosis and cirrhosis (Neuman, et al., 2015). Studies show that elevated levels of 1136 
the pro-inflammatory cytokine TNF-α is a consequence of chronic alcohol 1137 
consumption, which plays a crucial role in alcoholic hepatitis (Arteel, 2003; 1138 
Neuman, et al., 2015). Excessive alcohol consumption induces the translocation 1139 
of gut endotoxins to portal circulation by increasing gut permeability. This 1140 
translocation occurs due to the intestinal epithelium damage resulting from 1141 
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alcohol metabolites such as acetaldehyde (Jampana and Khan, 2011; Hartmann 1142 
et al., 2012; Chassaing et al., 2014). This in turn increases the level of the 1143 
bacterial products, lipopolysaccharides (LPS), in circulation and thus elevates the 1144 
exposure of the liver to LPS. This exposure will then induce the activation of toll-1145 
like receptor 4 (TLR4), a vital constituent of the innate immune system. In turn, 1146 
this will stimulate the activation of inflammatory cells like Kupffer cells (Jampana 1147 
and Khan, 2011). The activation of Kupffer cells consequently induces liver 1148 
inflammation and fibrosis by increasing the release of TNF-α (Kawaratani et al., 1149 
2017). 1150 
This study evaluated hepatic injury by measuring the concentration of the pro-1151 
inflammatory cytokine (TNFα) and some biomarkers of liver damage. The results 1152 
showed an increase in the levels of all liver enzymes AST, ALT, ALP and GGT 1153 
as well as the concentration of TNF-α (Figures 3.20 and 3.21). These findings 1154 
agree with Das and Vasudevan (2005) in which alkaline phosphatise (ALP), AST, 1155 
ALT and gamma-glutamyl transferase (GGT) were high in ALD patients. Other 1156 
studies have also reported similar findings with elevated serum levels of TNFα, 1157 
ALT and AST in rats exposed to binge alcohol for 16 weeks (Zhou et al., 2013) 1158 
or a high-alcohol liquid diet (Peng et al. 2012). In summary, these studies 1159 
demonstrated the relation between chronic alcohol consumption and its 1160 
contribution to liver injury. Moreover, binge alcohol drinking also corresponds to 1161 
elevated concentrations of liver enzymes and pro-inflammatory cytokines. The 1162 
correlation of these markers with indices of steatosis and fibrosis would aid the 1163 
usefulness of these liver markers in ALD pathogenesis. 1164 
 1165 
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 1167 
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5.1 Conclusion 1191 
Fatty liver disease is one of the most prevalent diseases worldwide and can be 1192 
caused by either excessive alcohol consumption (60 g/day) or a high dietary ratio 1193 
(>15:1) of the omega 6 and 3 fatty acids.  The development of fatty liver disease 1194 
can lead onto hepatitis, fibrosis and cirrhosis.  In NAFLD progression to end stage 1195 
cirrhosis is also highly associated with hepatic carcinoma, the 4th most 1196 
commonest cancer. Thus, understanding the early mechanisms in fatty liver 1197 
disease is crucial to elucidate improved treatment modalities as well as 1198 
preventing disease progression.  The main objectives of this project were 1199 
therefore to determine the effect of fatty acids on cell viability, lipid accumulation 1200 
and mitochondrial function. 1201 
It was revealed in this study that omega 6 fatty acids have a deleterious impact 1202 
on the liver cell. This was indicated by the higher reduction in the viability of the 1203 
cells with high arachidonic acid (AA) concentrations (30 and 80 µM) especially at 1204 
the 72h time point (Figure 3.4) than with linoleic acid (LA). This reduction with AA 1205 
was accompanied by a significant increase in lipid accumulation at 48 h, which 1206 
can be attributed to the high toxicity of AA possibly due to the effect of its 1207 
proinflammatory eicosanoids (Patterson et al., 2012; Kirack et al., 2015; 1208 
Maciejewska et al., 2015). Also, high level of lipid accumulation itself may lead to 1209 
ER stress and cell death (Wang et al., 2006).  1210 
On the other hand, individual omega 3 fatty acids alpha linolenic acid (ALA) and 1211 
docosahexaenoic acid (DHA) did not cause any change in either cell viability or 1212 
lipid accumulation. This is because of their protective capability in reducing 1213 
oxidative stress, attenuating the activity of lipogenic pathways such as SCD1 and 1214 
SREBP as well as activating transcriptional factors involved in lipid oxidation such 1215 
as PPARα. Several studies suggest a correlation between increased omega 6/3 1216 
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ratio and the development of NAFLD (Araya et al., 2004; Patterson et al., 2012). 1217 
Our findings are not entirely agreeable to other works whereby LA/ALA did not 1218 
cause hepatic steatosis, reflecting the different experimental conditions or the 1219 
need to increase the concentration of omega 6 in the ratios. However, AA/DHA 1220 
ratio showed a greater impact with high ratios (15:1-25:1) on liver steatosis and 1221 
cytotoxicity (Figure 3.8) which is consistent to other work (Araya et al., 2004; Puri 1222 
et al., 2007; Enos et al., 2015). 1223 
It is known that the dysregulation of lipid metabolism in the liver plays a crucial 1224 
role in the development of liver steatosis and which is a precursor to 1225 
steatohepatitis. The imbalance of AA/DHA ratio and the low concentration of 1226 
omega 3 (DHA) could be the reason behind the increased concentration of TG in 1227 
this study with high AA/DHA ratios (15:1 and 25:1), since low DHA and high AA 1228 
concentrations affects the oxidation of fatty acids and possible decreased export 1229 
of TG from liver cells shifting the pathway toward TG synthesis. 1230 
 1231 
In agreement with the above statement, in the present study the increase in lipid 1232 
accumulation appeared to correlate with the expression of transcriptional factors 1233 
involved in fat metabolism. Expression of SCD1, an enzyme involved in 1234 
lipogenesis, but not SREBP1 was up-regulated with high AA/DHA ratios. This in 1235 
turn, revealed that SCD1 is possibly not regulated by the activation of SREBP 1236 
and more likely is up-regulated by its direct binding to LXR. High omega ratios 1237 
were also able to down regulate the expression of PPARα and consequently the 1238 
oxidation of fatty acids which in turn, gives arise to steatosis supporting the role 1239 
of lipid dysregulation due to the imbalance in omega AA/DHA ratios.       1240 
    1241 
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It is also thought that high dietary fat affects the cannabinoid system and 1242 
consequently, stimulates lipid synthesis by regulating the expression of key 1243 
transcriptional genes involved in lipid metabolism. High AA/DHA ratios (15:1 and 1244 
25:1) was capable to induce hepatic steatosis and slightly increase the 1245 
expression of CB1 although this did not achieve statistical significance, which 1246 
possibly can be attributed to the short incubation time. Although CB2 receptor 1247 
expression did not show any increase with all ratios relative to the control, 1248 
expression of CB2 with 15:1 and 25:1 ratios were significantly higher than lower 1249 
ratios (1:1). This result requires further investigation but does suggest some 1250 
upregulation in CB2 expression but perhaps due to the short exposure time, is 1251 
not sufficient to induce liver injury as it is believed that CB2 expression normally 1252 
increases in advanced stages such as fibrosis and cirrhosis. However, what had 1253 
been obtained here is consistence with the SCD1 and PPARα data in which high 1254 
ratios induced lipid synthesis and stimulated the development of steatosis. 1255 
    1256 
Liver injury is highly correlated with a high calorific diet, free fatty acid delivery to 1257 
the liver and hepatic steatosis. High AA/DHA ratios were correlated with the 1258 
induction of liver injury and mitochondrial dysfunction (Figure 3.14). The 1259 
disturbance in mitochondrial function was represented by the low respiratory rate, 1260 
decrease in ATP production, along with a reduction in the proton leak as well as 1261 
an increase in ROS production. The impairment of mitochondrial oxidative 1262 
respiration reduced the ability of the cell to achieve its maximal respiration and to 1263 
respond to increased energy demand. The increase in ROS production and 1264 
mitochondrial dysfunction could possibly come from electron leakage due to the 1265 
destabilisation of cytochrome c by fatty acids in the ETC and consequently 1266 
reduces the flow of the electron along the respiratory chain causing increased 1267 
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release of electrons from the mitochondrial membrane. Also, it could be due to 1268 
the ability of the fatty acids to increase the permeability of the mitochondrial 1269 
membrane causing a reduction in the mitochondrial membrane potential, 1270 
uncoupling which subsequently leads to mitochondrial swelling and a reduction 1271 
in the production of ATP as it was indicated in this study. In addition, the increase 1272 
in ROS production resulted as a consequence of mitochondrial dysfunction and 1273 
the inhibition of complex I and III by AA in which the leakage of the electrons was 1274 
increased and consequently the production of ROS (Figure 3.12A,B). 1275 
 1276 
There is limited information on the interaction between alcohol and fatty acids.  It 1277 
is possible that some individuals are consuming high amounts of alcohol in 1278 
addition to a high calorific diet, making them susceptible to higher degrees of liver 1279 
injury due to the combined damaging effects. However, when alcohol was 1280 
combined for 24 hr with increasing AA/DHA ratios no effect on cell viability was 1281 
observed. Despite no increase in cell death there was a marked increase in the 1282 
level of ROS with high AA/DHA ratios (15:1 and 25:1) in the presence of alcohol. 1283 
This possibly was caused by the induction of CYP2E1 by the high fatty acid 1284 
treatment producing ROS, and not alcohol as the latter alone did not show any 1285 
effect on ROS. Furthermore, alcohol can be metabolised rapidly by both CYP2E1 1286 
and ADH enzymes reducing excess NADH production via ADH and thus limiting 1287 
mitochondrial ROS production.  Therefore, it seems that high AA/DHA ratios in 1288 
the presence of alcohol induces CYP2E1 and consequently leads to increase the 1289 
production of ROS causing mitochondrial dysfunction. Thus, these initial studies 1290 
require further investigation to explore the possible combined effect of alcohol 1291 
and fatty acids. It is possible that higher alcohol concentrations and longer 1292 
exposure times are required to provide a more accurate information of this 1293 
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interaction. Finally, many of the pathological mechanisms that occur with NAFLD 1294 
also occur in ALD, such as gut permeability injury.  Here it was observed that 1295 
chronic alcohol consumption is highly correlated to the elevated level of liver 1296 
injury markers as well as the pro-inflammatory cytokine, TNFα in ALD patients.  1297 
It is possible that similar effects would be observed in NAFLD patients due to high 1298 
AA/DHA ratios. 1299 
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Figure 5.1: Pathways affected by high omega 6/3 ratio. 1308 
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5.2 Future work  1317 
It has been demonstrated that saturated fatty acids PA and SA caused a 1318 
reduction in cell viability whereas only PA showed an increase in lipid 1319 
accumulation. Whilst this demonstrates the effect of saturated fatty acids, further 1320 
studies are needed to investigate the effect of saturated fatty acids as a ratio with 1321 
unsaturated fatty acids on cell toxicity and lipid accumulation. This can be also 1322 
achieved by evaluating the expression of key transcriptional factors involved in 1323 
lipid metabolism. These studies will provide further insight into the role of fatty 1324 
acids in NAFLD. 1325 
 1326 
With reference to the effect of omega fatty acids, it was illustrated that omega 6 1327 
AA was more toxic than LA, which can be due to its immediate pro-inflammatory 1328 
mediators through the degradation of these fatty acids by lipoxygenase (LOX) 1329 
and cyclo-oxygenase (COX) for AA and only LOX for LA.  To further investigate 1330 
the toxicity of these fatty acids, it would be helpful to evaluate the concentration 1331 
of eicosanoids produced from AA and LA as well as the activity of LOX enzyme 1332 
which is involved in metabolising AA and LA fatty acids. Data from omega 3, ALA 1333 
and DHA fatty acids revealed the protective property of this type of fatty acids, as 1334 
both ALA and DHA did not cause any lipotoxicity or lipid accumulation. This in 1335 
turn, calls for a further work to study the effect of individual omega 3 fatty acids 1336 
in NAFLD, their effect on the antioxidant-like nitric oxide (NO) and on the 1337 
expression of transcriptional factors involved in lipid oxidation such as PPARα or 1338 
its target enzymes, carnitine palmitoyltransferase-1.  1339 
 1340 
As mentioned in the section on the effect of increased omega 6/3 ratio on cell 1341 
viability, LA/ ALA ratios were not capable to induce cytotoxicity or increase the 1342 
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accumulation of lipid which can be due to the low concentration of LA being used, 1343 
since high concentrations of Individual LA (200 and 300 µM) was capable to 1344 
induce lipotoxcity. This in turn, points to the need of increasing the concentration 1345 
of LA in the LA/ALA ratios to show whether these ratios will induce any 1346 
cytotoxicity or not. The capability of high AA/DHA (15:1 and 25:1) ratios to reduce 1347 
cell viability occurs possibly due to inflammatory mediators of AA. Further work 1348 
measuring these key proinflammatory mediators is required. 1349 
 1350 
To further investigate lipid accumulation due to AA/DHA treatment, studies by 1351 
Western blotting should investigate whether these ratios decrease the expression 1352 
of vital enzymes involved in fatty acid oxidation such as carnitine 1353 
palmitoyltransferase-1 or increase the expression of key enzymes involved in 1354 
lipogenesis like Acetyl-CoA carboxylase or fatty acid synthase. It is also important 1355 
to evaluate the expression of LXR as it is correlated to the activation of SREBP-1356 
1c. Moreover, AA/DHA ratios did not cause any change in the expression of 1357 
SREBP1. Therefore, using another method other than western blotting to 1358 
evaluate the expression of SREBP1c can possibly show the effect of the 1359 
increased AA/DHA ratios on SREBP1c. These studies as well as evaluating the 1360 
expression of endocannabinoids (2-arachidonoylglycerol (2-AG) and 1361 
archidonoylethanolamide (anandamide) and inflammatory or fibrogenic markers 1362 
will also help in clarifying the impact of these ratios on the activation of CB1 and 1363 
CB2 receptors.  1364 
 1365 
In regard to the effect of high AA/DHA ratios on mitochondrial function and ROS 1366 
production. The findings of the current study showed a significant reduction in 1367 
mitochondrial function with an increase in the production of ROS. A study looking 1368 
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at the mitochondrial membrane potential by flow cytometry using rhodamine123 1369 
would also illuminate the potential impact of these ratios on mitochondrial 1370 
function. Also, investigating the expression of CYP2E1 would be valuable in 1371 
understanding the role of this enzyme in increasing the production of ROS with 1372 
high AA/DHA ratios.  1373 
 1374 
High AA/DHA ratios data in the presence of alcohol indicated a significant 1375 
increase in the level of ROS and caused cellular cytotoxicity. However, these 1376 
results could be as an effect of high AA/DHA ratio and not alcohol (100 mM) as 1377 
the concentration of alcohol may be low and needs to be increased and further 1378 
experimental investigations on the impact of these treatments using either 1379 
different type of cells or higher alcohol concentration would be useful. The results 1380 
of this study are encouraging and should be also validated by investigating the 1381 
impact of AA/DHA ratios in the presence of alcohol on mitochondrial function and 1382 
on the expression of fundamental enzymes involved in alcohol metabolism like 1383 
CYP2E1, alcohol dehydrogenase or aldehyde dehydrogenase, to further 1384 
elucidate mechanisms of alcoholic fatty liver development and prevention. 1385 
   1386 
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 1391 
 1392 
 1393 
 1394 
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Appendix  2128 
 2129 
Concentrations used in the preparation of omega 6/3 ratios 2130 
 2131 
A. Concentrations of linoleic acid (LA) and alpha linolenic acid (ALA) used in the 2132 
preparation of LA/ALA ratios: 2133 
LA/ALA 
ratio 
LA concentration 
(µM) 
ALA 
concentration 
(µM) 
1:1 30 30 
2:1 30 15 
4:1 30 7.5 
10:1 30 3 
15:1 30 2 
25:1 30 1.2 
 2134 
 2135 
 2136 
 2137 
 2138 
 2139 
 2140 
  
151 
 
 2141 
 2142 
B. Concentrations of arachidonic acid (AA) and docosahexaenoic acid (DHA) 2143 
used in the preparation of AA/DHA ratios: 2144 
AA/DHA 
ratio 
AA concentration 
(µM) 
DHA concentration 
(µM) 
1:1 2 2 
4:1 8 2 
15:1 30 2 
25:1 50 2 
 2145 
 2146 
 2147 
 2148 
 2149 
